US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
US6693176B1
(en)
*
|
1999-07-23 |
2004-02-17 |
University Of Massachusetts |
Antitumor antibodies, proteins, and uses thereof
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US7598055B2
(en)
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
US8697394B2
(en)
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
PT1522590E
(pt)
|
2000-06-28 |
2009-10-26 |
Glycofi Inc |
Métodos para a produção de glicoproteínas modificadas
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US7625756B2
(en)
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
EP3263702A1
(en)
*
|
2000-10-06 |
2018-01-03 |
Kyowa Hakko Kirin Co., Ltd. |
Cells producing antibody compositions
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
ES2390425T3
(es)
|
2000-12-22 |
2012-11-12 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
|
IL157736A0
(en)
*
|
2001-03-06 |
2004-03-28 |
Dow Chemical Co |
Plant cell having animal-type sugar chain adding function
|
KR100988949B1
(ko)
*
|
2001-10-25 |
2010-10-20 |
제넨테크, 인크. |
당단백질 조성물
|
WO2003049704A2
(en)
*
|
2001-12-11 |
2003-06-19 |
University Of Massachusetts |
Antibodies to treat cancer
|
US20040093621A1
(en)
*
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
EP2359685B1
(en)
|
2001-12-27 |
2013-12-04 |
GlycoFi, Inc. |
Methods to engineer mammalian-type carbohydrate structures
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US6964784B2
(en)
*
|
2002-03-07 |
2005-11-15 |
Optigenex, Inc. |
Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
|
EP1498491A4
(en)
*
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
DE60336548D1
(de)
*
|
2002-04-09 |
2011-05-12 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
US20050031613A1
(en)
*
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
PL373256A1
(en)
*
|
2002-04-09 |
2005-08-22 |
Kyowa Hakko Kogyo Co, Ltd. |
Cells with modified genome
|
EP1498490A4
(en)
*
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
EP1500400A4
(en)
*
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
AU2002338020A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody against blood-solubilized n-terminal peptide in gpc3
|
FR2844455B1
(fr)
*
|
2002-09-13 |
2007-12-14 |
Lab Francais Du Fractionnement |
Traitement des pathologies echappant a la reponse immune par des anticorps optimises
|
CN101987871A
(zh)
|
2002-09-27 |
2011-03-23 |
赞科股份有限公司 |
优化的Fc变体及其产生方法
|
US20040115204A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Fanger Gary R. |
Antibodies to treat cancer
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
JP4739954B2
(ja)
|
2003-03-13 |
2011-08-03 |
中外製薬株式会社 |
変異受容体に対するアゴニスト活性を有するリガンド
|
WO2004087757A2
(en)
*
|
2003-04-03 |
2004-10-14 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Antibodies with enhanced ability to immunomodulate cell functions
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
EP2228445A1
(en)
|
2003-06-18 |
2010-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose Transporter
|
EP2204190A1
(en)
|
2003-07-15 |
2010-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM production by transformed cells and methods for quantifying said IgM production
|
FR2858235B1
(fr)
*
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
WO2005014651A1
(ja)
|
2003-08-11 |
2005-02-17 |
Chugai Seiyaku Kabushiki Kaisha |
糖鎖改変抗hm1.24抗体
|
ATE528397T1
(de)
|
2003-08-08 |
2011-10-15 |
Perseus Proteomics Inc |
Bei krebs überexprimiertes gen
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
WO2005035586A1
(ja)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
融合蛋白質組成物
|
AU2004279739A1
(en)
*
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Composition of antibody capable of specifically binding CCR4
|
US20050226867A1
(en)
*
|
2003-10-08 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
IL-5R-specific antibody composition
|
US20050287138A1
(en)
*
|
2003-10-08 |
2005-12-29 |
Kyowa Hakko Kogyo Co., Ltd. |
CCR4-specific antibody composition
|
WO2005035583A1
(ja)
*
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Il-5受容体に特異的に結合する抗体組成物
|
JP4762717B2
(ja)
|
2003-10-09 |
2011-08-31 |
中外製薬株式会社 |
IgM高濃度安定化溶液
|
US20070128691A1
(en)
*
|
2003-10-09 |
2007-06-07 |
Ryosuke Nakano |
Genomically modified cell neutralized to serum-free system
|
US20060021071A1
(en)
*
|
2003-10-09 |
2006-01-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell in which genome is modified
|
AU2004280065A1
(en)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
WO2005035741A1
(ja)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
ゲノムが改変された細胞
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
LT2380911T
(lt)
|
2003-11-05 |
2018-07-10 |
Roche Glycart Ag |
Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
WO2005053742A1
(ja)
*
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
MXPA06005941A
(es)
|
2003-12-10 |
2006-08-23 |
Medarex Inc |
Anticuerpos ip-10 y sus usos.
|
CA2546054C
(en)
|
2003-12-10 |
2014-05-13 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
AU2004299053B2
(en)
*
|
2003-12-15 |
2011-01-06 |
Alexion Pharmaceuticals, Inc. |
Novel anti-DC-SIGN antibodies
|
RU2369616C2
(ru)
|
2003-12-30 |
2009-10-10 |
Мерк Патент Гмбх |
Слитые белки il-7
|
JP2005224240A
(ja)
*
|
2004-01-13 |
2005-08-25 |
Kyowa Hakko Kogyo Co Ltd |
ノックアウト非ヒト動物から樹立された不死化細胞株
|
ES2330860T3
(es)
|
2004-01-22 |
2009-12-16 |
Merck Patent Gmbh |
Anticuerpos anticancerosos con fijacion del complemento reducida.
|
JP4932699B2
(ja)
*
|
2004-03-17 |
2012-05-16 |
グライコフィ, インコーポレイテッド |
真菌および酵母におけるシチジンモノホスフェート−シアル酸合成経路を操作する方法
|
CA2561264A1
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
AU2005249566B2
(en)
*
|
2004-06-04 |
2010-11-11 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
MXPA06014067A
(es)
*
|
2004-06-04 |
2007-02-15 |
Genentech Inc |
Metodo para tratar lupus.
|
KR101541658B1
(ko)
|
2004-06-21 |
2015-08-07 |
메다렉스, 엘.엘.시. |
인터페론 알파 수용체 1 항체 및 그의 용도
|
CN111925445A
(zh)
|
2004-07-09 |
2020-11-13 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
EP1765871A1
(en)
|
2004-07-14 |
2007-03-28 |
Igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG |
N-glycosylated antibody
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
AU2005272993B2
(en)
|
2004-07-15 |
2010-02-11 |
Xencor, Inc |
Optimized Fc variants
|
US7871613B2
(en)
|
2004-08-24 |
2011-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Adjuvant therapy with the use of anti-glypican 3 antibody
|
KR20070100228A
(ko)
|
2004-10-05 |
2007-10-10 |
제넨테크, 인크. |
혈관염의 치료 방법
|
BRPI0518279A2
(pt)
*
|
2004-10-26 |
2008-11-11 |
Chugai Pharmaceutical Co Ltd |
anticorpo antiglipicam 3 tendo cadeia de aÇécar modificada
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP2208783A1
(en)
|
2004-12-22 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
|
PL1871805T3
(pl)
|
2005-02-07 |
2020-03-31 |
Roche Glycart Ag |
Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
|
DK1853718T3
(en)
|
2005-02-15 |
2015-11-09 |
Univ Duke |
ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
|
JP5249587B2
(ja)
|
2005-02-18 |
2013-07-31 |
メダレックス, インク. |
フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体
|
EP2535355B1
(en)
|
2005-03-23 |
2019-01-02 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
CA2604885A1
(en)
|
2005-04-07 |
2006-10-19 |
Guoying Yu |
Cacna1e in cancer diagnosis, detection and treatment
|
US20090220495A1
(en)
|
2005-04-07 |
2009-09-03 |
Abdallah Fanidi |
Cancer Related Genes (PRLR)
|
WO2006113665A2
(en)
|
2005-04-15 |
2006-10-26 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
ES2427646T5
(es)
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
KR20080046135A
(ko)
|
2005-05-20 |
2008-05-26 |
제넨테크, 인크. |
자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
CN103145842A
(zh)
|
2005-06-30 |
2013-06-12 |
Abbvie公司 |
Il-12/p40结合蛋白
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
AU2006279945B2
(en)
|
2005-08-10 |
2012-04-12 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant FC regions and methods of using same
|
BRPI0615026A8
(pt)
|
2005-08-19 |
2018-03-06 |
Abbott Lab |
imunoglobulina de domínio variável duplo e seus usos
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500358A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2619298C
(en)
|
2005-08-26 |
2017-07-04 |
Glycart Biotechnology Ag |
Modified antigen binding molecules with altered cell signaling activity
|
CA2621236A1
(en)
*
|
2005-08-31 |
2007-03-08 |
Centocor, Inc. |
Host cell lines for production of antibody constant region with enhanced effector function
|
JP2009507040A
(ja)
*
|
2005-09-02 |
2009-02-19 |
グライコフィ, インコーポレイテッド |
主としてglcnacman3glcnac2糖形態を含む免疫グロブリン
|
JP2009507482A
(ja)
*
|
2005-09-09 |
2009-02-26 |
グライコフィ, インコーポレイテッド |
主にman7glcnac2、man8glcnac2グリコフォームを含むイムノグロブリン
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
JPWO2007046439A1
(ja)
|
2005-10-18 |
2009-04-23 |
独立行政法人農業生物資源研究所 |
抗体を産生するトランスジェニックカイコとその製造方法
|
SI1945665T1
(sl)
|
2005-10-21 |
2012-03-30 |
Genzyme Corp |
Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
|
EP2532679B1
(en)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
EP2455100A3
(en)
*
|
2005-11-07 |
2012-11-07 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
KR20140087058A
(ko)
|
2005-11-30 |
2014-07-08 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
PT2289909E
(pt)
|
2005-11-30 |
2015-02-10 |
Abbvie Inc |
Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
|
WO2007126439A2
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
PL1960434T3
(pl)
|
2005-12-08 |
2012-12-31 |
Squibb & Sons Llc |
Ludzkie przeciwciała monoklonalne przeciw fozylowi-gm1 i sposoby zastosowania antyfukozylu-gm1
|
JP5175214B2
(ja)
|
2005-12-30 |
2013-04-03 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
改良された安定性を有するインターロイキン−12p40変種
|
KR101397290B1
(ko)
|
2005-12-30 |
2014-05-21 |
메르크 파텐트 게엠베하 |
감소한 면역원성을 가지는 항-cd19 항체
|
US20090155821A1
(en)
*
|
2006-01-04 |
2009-06-18 |
John Kunich |
Antibody-dependent cellular cytotoxicity assay
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
CA2637254A1
(en)
|
2006-01-17 |
2007-07-26 |
Biolex Therapeutics, Inc. |
Compositions and methods for humanization and optimization of n-glycans in plants
|
EP2397148A3
(en)
|
2006-02-02 |
2012-04-25 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2389951A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
US20080014203A1
(en)
*
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
AU2007256617A1
(en)
*
|
2006-06-06 |
2007-12-13 |
Genentech, Inc. |
Compositions and methods for modulating vascular development
|
MX2008015541A
(es)
|
2006-06-06 |
2008-12-18 |
Genentech Inc |
Anticuerpos anti-dll4 y metodos que los usan.
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
ME01786B
(me)
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimizovana antitela usmerena na cd19
|
JP5317697B2
(ja)
|
2006-08-14 |
2013-10-16 |
中外製薬株式会社 |
抗Desmoglein3抗体を用いる癌の診断および治療
|
KR20090088852A
(ko)
|
2006-09-05 |
2009-08-20 |
메다렉스, 인코포레이티드 |
골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
|
WO2008031056A2
(en)
|
2006-09-08 |
2008-03-13 |
Medimmune, Llc |
Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
UA115964C2
(uk)
|
2006-09-08 |
2018-01-25 |
Еббві Айрленд Анлімітед Компані |
Інтерлейкін-13-зв'язувальний білок
|
ES2533964T5
(es)
|
2006-09-10 |
2024-05-09 |
Glycotope Gmbh |
Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
AU2007320024B2
(en)
|
2006-10-02 |
2012-11-08 |
E. R. Squibb & Sons, L.L.C. |
Human antibodies that bind CXCR4 and uses thereof
|
CA2665528C
(en)
|
2006-10-12 |
2018-01-23 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-ereg antibody
|
NZ576032A
(en)
|
2006-10-12 |
2012-03-30 |
Genentech Inc |
Antibodies to lymphotoxin-alpha
|
AU2007311957A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
AU2007334264A1
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to BTLA and methods of use
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
SG177168A1
(en)
|
2006-12-01 |
2012-01-30 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof
|
US20080127996A1
(en)
*
|
2006-12-04 |
2008-06-05 |
Weinhold Dennis G |
Method and apparatus to remediate an acid and/or liquid spill
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
NZ578354A
(en)
|
2006-12-14 |
2012-01-12 |
Medarex Inc |
Antibody-partner molecule conjugates that bind cd70 and uses thereof
|
JP5632582B2
(ja)
|
2006-12-14 |
2014-11-26 |
中外製薬株式会社 |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
WO2008090960A1
(ja)
|
2007-01-24 |
2008-07-31 |
Kyowa Hakko Kirin Co., Ltd. |
ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
EP2447719B1
(en)
|
2007-02-26 |
2016-08-24 |
Oxford BioTherapeutics Ltd |
Proteins
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
AU2008227024A1
(en)
*
|
2007-03-07 |
2008-09-18 |
Glycofi, Inc. |
Production of glycoproteins with modified fucosylation
|
CA2679986C
(en)
|
2007-03-08 |
2018-03-06 |
Martin Lackmann |
Epha3 antibodies for the treatment of solid tumors
|
CN101861168B
(zh)
|
2007-05-07 |
2014-07-02 |
米迪缪尼有限公司 |
抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
|
SG10201503254TA
(en)
|
2007-05-14 |
2015-06-29 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
MX2009013816A
(es)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos.
|
JP5469456B2
(ja)
|
2007-06-25 |
2014-04-16 |
中外製薬株式会社 |
ADCC活性又はCDC活性を有する抗Prominin−1抗体
|
JP5938816B2
(ja)
*
|
2007-07-04 |
2016-06-22 |
中外製薬株式会社 |
抗Muc17抗体
|
PL2178916T3
(pl)
*
|
2007-07-31 |
2015-08-31 |
Regeneron Pharma |
Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
US8501907B2
(en)
|
2007-08-10 |
2013-08-06 |
Janssen Biotech, Inc. |
Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
|
LT2769729T
(lt)
|
2007-09-04 |
2019-05-10 |
Compugen Ltd. |
Polipeptidai ir polinukleotidai ir jų panaudojimas kaip vaistų taikinio vaistų ir biologinių preparatų gamybai
|
AR068563A1
(es)
|
2007-09-26 |
2009-11-18 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo mutante
|
US20100260751A1
(en)
|
2007-09-28 |
2010-10-14 |
Raju T Shantha |
Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases
|
KR20150126724A
(ko)
*
|
2007-09-28 |
2015-11-12 |
추가이 세이야쿠 가부시키가이샤 |
혈장 중 반응속도가 개선된 항-글리피칸-3 항체
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
AU2008320823B2
(en)
|
2007-11-02 |
2013-01-17 |
Novartis Ag |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
|
MX2010005108A
(es)
|
2007-11-07 |
2010-05-27 |
Genentech Inc |
Composiciones y metodos para el tratamiento de trastornos microbianos.
|
CN102112492B
(zh)
|
2007-11-14 |
2015-02-25 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
EP2769993A1
(en)
|
2007-12-14 |
2014-08-27 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
CA2708871C
(en)
|
2007-12-21 |
2017-11-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
EP3825329A1
(en)
|
2007-12-26 |
2021-05-26 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
SG187457A1
(en)
|
2008-01-11 |
2013-02-28 |
Univ Tokyo |
Anti-cldn6 antibody
|
US20110033378A1
(en)
|
2008-01-18 |
2011-02-10 |
Medlmmune, Llc. |
Cysteine Engineered Antibodies For Site-Specific Conjugation
|
BRPI0906387A2
(pt)
|
2008-02-05 |
2015-07-07 |
Bristol Myers Squibb Co |
Anticorpos alfa 5 - beta 1 e seus usos
|
PT2250279E
(pt)
|
2008-02-08 |
2016-06-03 |
Medimmune Llc |
Anticorpos anti-ifnár1 com afinidade reduzida para o ligando fc
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
US8669349B2
(en)
|
2008-04-02 |
2014-03-11 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
JP4954326B2
(ja)
|
2008-04-11 |
2012-06-13 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
EP2281845B1
(en)
|
2008-04-25 |
2020-09-02 |
Kyowa Kirin Co., Ltd. |
Stable polyvalent antibody
|
CA2722466A1
(en)
|
2008-04-29 |
2009-11-05 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
US9296810B2
(en)
|
2008-05-02 |
2016-03-29 |
Novartis Ag |
Fibronectin-based binding molecules and uses thereof
|
ES2579554T3
(es)
|
2008-05-09 |
2016-08-12 |
Abbvie Deutschland Gmbh & Co Kg |
Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
WO2009149189A2
(en)
|
2008-06-03 |
2009-12-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP2282770B1
(en)
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
WO2010001908A1
(ja)
|
2008-06-30 |
2010-01-07 |
協和発酵キリン株式会社 |
抗cd27抗体
|
KR101054362B1
(ko)
*
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
|
TW201014602A
(en)
|
2008-07-08 |
2010-04-16 |
Abbott Lab |
Prostaglandin E2 binding proteins and uses thereof
|
DK2733492T3
(en)
|
2008-08-05 |
2016-04-25 |
Toray Industries |
Method for detection of cancer
|
MX356218B
(es)
|
2008-08-05 |
2018-05-18 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010018846A1
(ja)
*
|
2008-08-13 |
2010-02-18 |
協和発酵キリン株式会社 |
ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
EP2853545B8
(en)
|
2008-09-17 |
2023-04-05 |
Xencor, Inc. |
Antibody specific for IgE
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
EP2340305A1
(en)
|
2008-09-26 |
2011-07-06 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
EP3524620A1
(en)
|
2008-10-14 |
2019-08-14 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
AU2009325878B2
(en)
|
2008-12-08 |
2014-01-16 |
Compugen Ltd. |
TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
GB2466025A
(en)
|
2008-12-08 |
2010-06-09 |
Univ Francois Rabelais De Tour |
C3/ITGAM polymorphisms and cancer prognosis
|
SI2786762T1
(sl)
|
2008-12-19 |
2019-07-31 |
Macrogenics, Inc. |
Kovalentna diatelesa in njihove uporabe
|
WO2010074049A1
(ja)
|
2008-12-22 |
2010-07-01 |
株式会社 未来創薬研究所 |
抗hs6st2抗体及びその用途
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
WO2010073694A1
(ja)
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
JP5511686B2
(ja)
|
2008-12-26 |
2014-06-04 |
協和発酵キリン株式会社 |
抗cd4抗体
|
US20120014870A1
(en)
|
2008-12-26 |
2012-01-19 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
|
ES2539045T3
(es)
|
2009-01-19 |
2015-06-25 |
Innate Pharma |
Anticuerpos anti-KIR3D
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
MX2011009220A
(es)
|
2009-03-05 |
2011-09-28 |
Medarex Inc |
Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
|
AR075798A1
(es)
|
2009-03-05 |
2011-04-27 |
Abbott Lab |
Proteinas de union a il-17 (interleuquina 17)
|
AU2010221159B2
(en)
|
2009-03-06 |
2015-11-26 |
Humanigen, Inc. |
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
KR20130080871A
(ko)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
이중특이적 항-her 항체
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
CN104788564A
(zh)
|
2009-03-25 |
2015-07-22 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
CA2753988C
(en)
|
2009-03-25 |
2017-04-25 |
Genentech, Inc. |
Novel anti-.alpha.5.beta. integrin antibodies and uses thereof
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
JP5501439B2
(ja)
|
2009-04-02 |
2014-05-21 |
ロシュ グリクアート アクチェンゲゼルシャフト |
完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
BRPI1014449A2
(pt)
|
2009-04-07 |
2017-06-27 |
Roche Glycart Ag |
anticorpos biespecíficos anti-erbb-2/ anti-c-met.
|
MX2011010166A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-3/anti-c-met.
|
NZ605450A
(en)
|
2009-04-09 |
2014-07-25 |
Daiichi Sankyo Co Ltd |
Anti-siglec-15 antibody
|
US8647623B2
(en)
|
2009-04-10 |
2014-02-11 |
Kyowa Hakko Kirin Co., Ltd |
Method for treatment of blood tumor using anti-TIM-3 antibody
|
US9079957B2
(en)
|
2009-04-16 |
2015-07-14 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
|
EP2421898B1
(en)
|
2009-04-20 |
2016-03-16 |
Oxford BioTherapeutics Ltd |
Antibodies specific to cadherin-17
|
JP5694921B2
(ja)
|
2009-04-20 |
2015-04-01 |
協和発酵キリン株式会社 |
アミノ酸変異が導入されたIgG2を有する抗体
|
BRPI1016055A2
(pt)
|
2009-04-27 |
2016-05-10 |
Novartis Ag |
composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
|
CA2758290C
(en)
|
2009-04-27 |
2018-04-10 |
Novartis Ag |
Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
|
CA2764432C
(en)
|
2009-04-27 |
2017-10-24 |
Kyowa Hakko Kirin Co., Ltd. |
Interleukin-3 receptor alpha chain-binding antibody to treat leukemia
|
AU2010242338B2
(en)
|
2009-05-01 |
2013-12-19 |
Perseus Proteomics Inc. |
Anti-cadherin antibody
|
BRPI1011145A2
(pt)
|
2009-05-15 |
2016-03-15 |
Chugai Pharmaceutical Co Ltd |
anticorpo anti-axl
|
EP2435473B1
(en)
|
2009-05-27 |
2013-10-02 |
F.Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
US8815242B2
(en)
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
DK2438171T3
(en)
|
2009-06-02 |
2015-01-26 |
Regeneron Pharma |
Fucosylerings-deficient cells
|
BRPI1010759B1
(pt)
|
2009-06-11 |
2019-07-16 |
Inter-University Research Institute Corporation Research Organization Of Information And Systems |
Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
EP2443151A1
(en)
|
2009-06-18 |
2012-04-25 |
Pfizer Inc. |
Anti notch-1 antibodies
|
EP2445520A4
(en)
|
2009-06-22 |
2013-03-06 |
Medimmune Llc |
MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
SG177689A1
(en)
|
2009-07-31 |
2012-02-28 |
Organon Nv |
Fully human antibodies to btla
|
BR112012002819B1
(pt)
|
2009-08-07 |
2022-11-22 |
Kyowa Kirin Co., Ltd |
Anticorpo humanizado antioligômero de amiloide-b, seus usos, e formulação farmacêutica
|
JP5692073B2
(ja)
|
2009-08-07 |
2015-04-01 |
協和発酵キリン株式会社 |
抗アミロイドβオリゴマーヒト化抗体
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
JP2013501741A
(ja)
|
2009-08-14 |
2013-01-17 |
ロシュ グリクアート アーゲー |
アフコシル化cd20抗体とフルダラビン及び/又はミトキサントロンの併用療法
|
EP2468771A4
(en)
|
2009-08-17 |
2013-06-05 |
Forerunner Pharma Res Co Ltd |
PHARMACEUTICAL COMPOSITION WITH AN ANTIBODY TO HB-EGF AS AN ACTIVE SUBSTANCE
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
MX339608B
(es)
|
2009-08-31 |
2016-05-31 |
Roche Glycart Ag |
Anticuerpos del antigeno carcinoembrionario (cea).
|
AU2010289527C1
(en)
|
2009-09-01 |
2014-10-30 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
AU2010297580B2
(en)
|
2009-09-22 |
2014-07-31 |
Probiogen Ag |
Process for producing molecules containing specialized glycan structures
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
EP2488554B1
(en)
|
2009-10-14 |
2019-07-24 |
Humanigen, Inc. |
Antibodies to epha3
|
EP2488658A4
(en)
|
2009-10-15 |
2013-06-19 |
Abbvie Inc |
IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
|
AR078716A1
(es)
|
2009-10-22 |
2011-11-30 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso
|
NZ623607A
(en)
|
2009-10-23 |
2016-07-29 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
CN104928336B
(zh)
|
2009-10-26 |
2020-05-08 |
弗·哈夫曼-拉罗切有限公司 |
用于生产糖基化免疫球蛋白的方法
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
BR112012010252A2
(pt)
|
2009-10-29 |
2016-12-06 |
Janssen Biotech Inc |
variantes de glicosilação de anticorpo
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
BR112012010707B1
(pt)
|
2009-11-04 |
2022-08-30 |
Merck Sharp & Dohme Corp |
Anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, e, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
SI2496601T1
(sl)
|
2009-11-05 |
2017-09-29 |
F. Hoffmann-La Roche Ag |
Tehnike in sestavek za sekrecijo heterolognih polipeptidov
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
JP5951498B2
(ja)
|
2009-12-08 |
2016-07-13 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
網膜神経線維層変性の治療に使用するためのrgmaタンパク質に対するモノクローナル抗体
|
AR078377A1
(es)
|
2009-12-11 |
2011-11-02 |
Genentech Inc |
Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
|
SI2516469T1
(sl)
|
2009-12-22 |
2016-05-31 |
Roche Glycart Ag |
Protitelesa proti her3 in uporabe le-teh
|
KR20120107122A
(ko)
|
2009-12-22 |
2012-09-28 |
노파르티스 아게 |
치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
|
EP2516465B1
(en)
|
2009-12-23 |
2016-05-18 |
F.Hoffmann-La Roche Ag |
Anti-bv8 antibodies and uses thereof
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
SI2530091T1
(en)
|
2010-01-29 |
2018-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
PROTITELO ANTI-DLL3
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
CA2789310C
(en)
|
2010-02-10 |
2018-01-09 |
Fujifilm Ri Pharma Co., Ltd. |
Radioactive metal-labeled anti-cadherin antibody
|
WO2011098449A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
SI2536748T1
(sl)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
|
CN102985441B
(zh)
|
2010-02-19 |
2015-04-22 |
俄克拉何马大学董事会 |
抑制Wnt信号传导途径的单克隆抗体及其制备方法和用途
|
JPWO2011105573A1
(ja)
|
2010-02-26 |
2013-06-20 |
株式会社 未来創薬研究所 |
抗icam3抗体およびその用途
|
JP5820800B2
(ja)
|
2010-03-02 |
2015-11-24 |
協和発酵キリン株式会社 |
改変抗体組成物
|
HUE045487T2
(hu)
|
2010-03-04 |
2019-12-30 |
Macrogenics Inc |
B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
EP2552947A4
(en)
|
2010-03-26 |
2013-11-13 |
Dartmouth College |
VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
EP2554669B1
(en)
|
2010-03-26 |
2018-09-19 |
Kyowa Hakko Kirin Co., Ltd. |
Novel antibody having modification site introduced therein, and antibody fragment
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
MX341925B
(es)
|
2010-03-29 |
2016-09-07 |
Zymeworks Inc |
Anticuerpos con funcion efectora suprimida o mejorada.
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
ES2684475T3
(es)
|
2010-04-15 |
2018-10-03 |
Abbvie Inc. |
Proteínas que se unen a beta amiloide
|
RU2585489C2
(ru)
|
2010-04-27 |
2016-05-27 |
Рош Гликарт Аг |
КОМБИНИРОВАННАЯ ТЕРАПИЯ АФУКОЗИЛИРОВАННЫМ АНТИТЕЛОМ CD20 И ИНГИБИТОРОМ mTOR
|
JP2013527761A
(ja)
|
2010-05-06 |
2013-07-04 |
ノバルティス アーゲー |
治療的低密度リポタンパク質関連タンパク質6(lrp6)多価抗体の組成物および使用方法
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
TWI522365B
(zh)
|
2010-05-14 |
2016-02-21 |
艾伯維有限公司 |
Il-1結合蛋白
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
AU2011261161A1
(en)
|
2010-06-01 |
2013-01-10 |
Ludwig Institute For Cancer Research Limited |
Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
|
SG185430A1
(en)
|
2010-06-03 |
2012-12-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
EP3363499A1
(en)
|
2010-06-11 |
2018-08-22 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-tim-3 antibody
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
EP4269563A3
(en)
|
2010-06-19 |
2024-01-10 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
EP3327035A1
(en)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
US9534246B2
(en)
|
2010-07-01 |
2017-01-03 |
Glaxo Group Limited |
Method for selecting high producing cell lines
|
JP5619162B2
(ja)
|
2010-07-08 |
2014-11-05 |
本田技研工業株式会社 |
高周波加熱用コイル
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
JP2013535198A
(ja)
|
2010-07-30 |
2013-09-12 |
グリコド |
哺乳類のグリコシル化経路を有する酵母人工染色体
|
AU2011286024B2
(en)
|
2010-08-02 |
2014-08-07 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
BR112013002578A2
(pt)
|
2010-08-03 |
2019-05-14 |
Abbvie Inc. |
imunoglobinas de domínio variável duplo e usos das mesmas
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
TW201209063A
(en)
|
2010-08-13 |
2012-03-01 |
Roche Glycart Ag |
Anti-tenascin-C A2 antibodies and methods of use
|
BR112013003361B8
(pt)
|
2010-08-13 |
2022-01-25 |
Roche Glycart Ag |
Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
JP6057896B2
(ja)
|
2010-08-20 |
2017-01-11 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)に対する抗体
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CA2805054A1
(en)
|
2010-08-25 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Antibodies against il-18r1 and uses thereof
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
SG187965A1
(en)
|
2010-08-27 |
2013-04-30 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
CA2810016A1
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
WO2012035518A1
(en)
|
2010-09-17 |
2012-03-22 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
KR101814852B1
(ko)
|
2010-10-29 |
2018-01-04 |
다이이찌 산쿄 가부시키가이샤 |
신규 항 dr5 항체
|
BR112013011811A2
(pt)
|
2010-11-05 |
2023-02-23 |
Zymeworks Inc |
Modelo de anticorpo heterodimérico estável com mutações no domínio fc
|
SG190682A1
(en)
|
2010-11-10 |
2013-07-31 |
Genentech Inc |
Methods and compositions for neural disease immunotherapy
|
PT2644698T
(pt)
|
2010-11-17 |
2018-01-31 |
Chugai Pharmaceutical Co Ltd |
Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
|
US20120269834A1
(en)
*
|
2010-11-19 |
2012-10-25 |
Robert Jordan |
Immunoglobulin cleavage fragment vaccine compositions
|
CA2818813C
(en)
|
2010-11-23 |
2020-10-06 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of oral mucositis
|
PT2643352T
(pt)
|
2010-11-23 |
2018-08-01 |
Glaxo Group Ltd |
Proteínas de ligação a antigénio para a oncostatina m (osm)
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
EP4231014A3
(en)
|
2010-11-30 |
2024-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
KR101026999B1
(ko)
|
2010-12-08 |
2011-04-11 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
RU2016123839A
(ru)
|
2010-12-08 |
2018-11-30 |
АббВай Стемсентркс ЭлЭлСи |
Новые модуляторы и способы их применения
|
US9458240B2
(en)
|
2010-12-10 |
2016-10-04 |
Novartis Pharma Ag |
Anti-BAFFR antibody formulations
|
RU2598255C2
(ru)
|
2010-12-15 |
2016-09-20 |
Интер-Юниверсити Рисерч Инститьют Корпорейшн Рисерч Организейшн Оф Информейшн Энд Системз |
Способ получения белка
|
AU2011342162B2
(en)
|
2010-12-15 |
2017-04-20 |
Kyowa Kirin Co., Ltd. |
Method for producing proteins
|
WO2012080926A2
(en)
|
2010-12-15 |
2012-06-21 |
Wyeth Llc |
Anti-notch1 antibodies
|
US20120156194A1
(en)
|
2010-12-16 |
2012-06-21 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
MX2013006739A
(es)
|
2010-12-16 |
2013-07-17 |
Roche Glycart Ag |
Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
MY163368A
(en)
|
2010-12-21 |
2017-09-15 |
Abbvie Inc |
Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
NZ612379A
(en)
|
2010-12-23 |
2014-10-31 |
Janssen Biotech Inc |
Active protease-resistant antibody fc mutants
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
EP3763740A1
(en)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
FR2971250A1
(fr)
|
2011-02-07 |
2012-08-10 |
Univ Nantes |
Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
|
JP2014511147A
(ja)
|
2011-02-10 |
2014-05-12 |
ロシュ グリクアート アーゲー |
改善された免疫療法
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
RU2607038C2
(ru)
|
2011-02-28 |
2017-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Антигенсвязывающие белки
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
CA2827722C
(en)
|
2011-03-02 |
2020-05-12 |
Roche Glycart Ag |
Anti-cea antibodies
|
WO2012127045A1
(en)
|
2011-03-23 |
2012-09-27 |
Glycode |
A yeast recombinant cell capable of producing gdp-fucose
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
BR112013024717A2
(pt)
|
2011-04-07 |
2017-08-08 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
|
BR112013026199A2
(pt)
|
2011-04-15 |
2017-11-07 |
Compugen Ltd |
polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
|
EP2700652B1
(en)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnosis and treatment of cancer using anti-itm2a antibody
|
AU2012245491C1
(en)
|
2011-04-19 |
2017-12-21 |
Merrimack Pharmaceuticals, Inc. |
Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
TWI561531B
(en)
|
2011-04-25 |
2016-12-11 |
Daiichi Sankyo Co Ltd |
Anti b7-h3 antibody
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
NO2707391T3
(sh)
|
2011-05-13 |
2018-04-07 |
|
|
MY175338A
(en)
|
2011-05-16 |
2020-06-19 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CA2837184C
(en)
|
2011-05-25 |
2021-09-21 |
Innate Pharma, S.A. |
Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Bcma(cd269/tnfrsf17)결합 단백질
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
WO2012174001A1
(en)
|
2011-06-13 |
2012-12-20 |
Abgenomics Cooperatief U.A. |
Anti-psgl-1 antibodies and uses thereof
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
AR086924A1
(es)
|
2011-06-15 |
2014-01-29 |
Hoffmann La Roche |
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
|
MX2013014789A
(es)
|
2011-06-16 |
2014-01-20 |
Novartis Ag |
Proteinas solubles para utilizarse como productos terapeuticos.
|
US20140120555A1
(en)
*
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
KR20140033152A
(ko)
|
2011-06-20 |
2014-03-17 |
교와 핫꼬 기린 가부시키가이샤 |
항erbB3 항체
|
AR086982A1
(es)
|
2011-06-22 |
2014-02-05 |
Hoffmann La Roche |
Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i
|
JP6120833B2
(ja)
|
2011-06-22 |
2017-04-26 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) |
抗Axl抗体及びその使用
|
US9249228B2
(en)
|
2011-06-22 |
2016-02-02 |
Oribase Pharma |
Anti-Axl antibodies and uses thereof
|
FR2976811A1
(fr)
|
2011-06-22 |
2012-12-28 |
Lfb Biotechnologies |
Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
|
KR102058185B1
(ko)
|
2011-06-28 |
2019-12-20 |
옥스포드 바이오테라퓨틱스 리미티드 |
Adp-리보실 시클라제 2에 대한 항체
|
RS55716B1
(sr)
|
2011-06-28 |
2017-07-31 |
Oxford Biotherapeutics Ltd |
Terapeutski i dijagnostički cilj
|
EP2726503B1
(en)
|
2011-06-30 |
2019-09-04 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
CA2835242A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
EP2734236A4
(en)
|
2011-07-13 |
2015-04-15 |
Abbvie Inc |
METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
|
EP2731970B1
(en)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
PE20141659A1
(es)
|
2011-07-27 |
2014-11-21 |
Glaxo Group Ltd |
Dominios variables singulares anti-vgf fusionados con dominios de fc
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
MX2014001736A
(es)
|
2011-08-17 |
2014-03-31 |
Genentech Inc |
Inhibicion de angiogenesis en tumores refractarios.
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
US9309306B2
(en)
|
2011-08-23 |
2016-04-12 |
Roche Glycart Ag |
Anti-MCSP antibodies
|
CN103857700A
(zh)
|
2011-08-26 |
2014-06-11 |
梅里麦克制药股份有限公司 |
串联fc双特异性抗体
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
RU2014114119A
(ru)
|
2011-09-23 |
2015-10-27 |
Рош Гликарт Аг |
Биспецифические анти-egfr/анти igf-1r-антитела
|
NZ721184A
(en)
|
2011-09-30 |
2018-08-31 |
Dana Farber Cancer Inst Inc |
Therapeutic peptides
|
WO2013047729A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
標的抗原に対する免疫応答を誘導する抗原結合分子
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP2762493B1
(en)
|
2011-09-30 |
2021-06-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
SG11201401287SA
(en)
|
2011-10-05 |
2014-05-29 |
Genentech Inc |
Methods of treating liver conditions using notch2 antagonists
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP2766392B1
(en)
|
2011-10-10 |
2019-07-17 |
Xencor, Inc. |
A method for purifying antibodies
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
CN104080471B
(zh)
|
2011-10-14 |
2018-08-10 |
诺华股份有限公司 |
用于Wnt途径相关疾病的抗体和方法
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
EP2772268B8
(en)
|
2011-10-28 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
TW201325613A
(zh)
|
2011-10-28 |
2013-07-01 |
Genentech Inc |
治療黑色素瘤之治療組合及方法
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
AU2012332588B2
(en)
|
2011-11-01 |
2017-09-07 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
RS62689B1
(sr)
|
2011-11-04 |
2021-12-31 |
Zymeworks Inc |
Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
ES2749349T3
(es)
|
2011-11-07 |
2020-03-19 |
Medimmune Llc |
Proteínas de unión multiespecíficas y multivalentes y usos de las mismas
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
JP6243345B2
(ja)
|
2011-12-05 |
2017-12-06 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)に対する抗体
|
WO2013084148A2
(en)
|
2011-12-05 |
2013-06-13 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
WO2013087789A1
(en)
|
2011-12-13 |
2013-06-20 |
Glykos Finland Ltd. |
Antibody isoform arrays and methods thereof
|
LT2794905T
(lt)
|
2011-12-20 |
2020-07-10 |
Medimmune, Llc |
Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
|
CN106831985A
(zh)
|
2011-12-21 |
2017-06-13 |
诺华股份有限公司 |
用于抗体靶定p因子的组合物和方法
|
SG11201403445YA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Full length antibody display system for eukaryotic cells and its use
|
EP2794651B1
(en)
|
2011-12-22 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
US9963511B2
(en)
|
2011-12-22 |
2018-05-08 |
Hoffmann-La Roche Inc. |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
WO2013102042A2
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
SG10201601747XA
(en)
|
2012-01-18 |
2016-04-28 |
Genentech Inc |
Anti-LRP5 Antibodies And Methods Of Use
|
PE20142168A1
(es)
|
2012-01-27 |
2015-01-17 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
CN104185681A
(zh)
|
2012-02-01 |
2014-12-03 |
卡姆普根有限公司 |
C1orf32抗体及其用于治疗癌症的用途
|
JP6405242B2
(ja)
|
2012-02-07 |
2018-10-17 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
Mica結合剤
|
US20150210763A1
(en)
|
2012-02-09 |
2015-07-30 |
Chugai Seiyaku Kabushiki Kaisha |
MODIFIED Fc REGION OF ANTIBODY
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
JP6545959B2
(ja)
|
2012-02-11 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
Rスポンジン転位およびその使用方法
|
ES2676031T3
(es)
|
2012-02-15 |
2018-07-16 |
F. Hoffmann-La Roche Ag |
Cromatografía de afinidad basada en el receptor Fc
|
CA2867444C
(en)
|
2012-03-16 |
2021-04-13 |
University Health Network |
Compositions containing soluble toso protein and uses thereof
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
WO2013147153A1
(ja)
|
2012-03-29 |
2013-10-03 |
株式会社未来創薬研究所 |
抗lamp5抗体およびその利用
|
WO2013147212A1
(ja)
|
2012-03-30 |
2013-10-03 |
第一三共株式会社 |
新規抗Siglec-15抗体
|
EP2832857B1
(en)
|
2012-03-30 |
2018-01-03 |
Daiichi Sankyo Company, Limited |
Cdr-modified anti-siglec-15 antibody
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
ES2831309T3
(es)
|
2012-04-09 |
2021-06-08 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-FGFR2
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9505833B2
(en)
|
2012-04-20 |
2016-11-29 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
JP5897205B2
(ja)
|
2012-04-27 |
2016-03-30 |
第一三共株式会社 |
抗robo4抗体
|
CN104470544B
(zh)
|
2012-05-01 |
2018-01-12 |
基因泰克公司 |
抗pmel17抗体和免疫缀合物
|
CA2872540A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
WO2013174927A1
(en)
|
2012-05-23 |
2013-11-28 |
Novartis International Pharmaceutical Limited |
Production of fucosylated glycoproteins
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
CA2869529A1
(en)
|
2012-05-24 |
2013-11-28 |
Raffaella CASTOLDI |
Multispecific antibodies
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
EP2855520B1
(en)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Site-specific labeling methods and molecules produced thereby
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
TW201410706A
(zh)
|
2012-06-15 |
2014-03-16 |
Genentech Inc |
抗-pcsk9抗體、調配物、劑量及使用方法
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CA2877533C
(en)
|
2012-06-22 |
2022-08-16 |
The Trustees Of Dartmouth College |
Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
ES2597228T3
(es)
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
HUE029435T2
(en)
|
2012-07-04 |
2017-02-28 |
Hoffmann La Roche |
Anti-theophylline antibodies and methods of their application
|
WO2014006124A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Covalently linked antigen-antibody conjugates
|
CA3188124A1
(en)
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
CA2877848C
(en)
|
2012-07-06 |
2021-11-02 |
St. Marianna University School Of Medicine |
Therapeutic method and medicament for htlv-1 associated myelopathy (ham)
|
EP2869847B1
(en)
|
2012-07-09 |
2017-12-06 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
CA2874904A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
AR091700A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b
|
SG11201500087VA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
WO2014009465A1
(en)
|
2012-07-13 |
2014-01-16 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
KR20150036710A
(ko)
|
2012-07-18 |
2015-04-07 |
글리코토페 게엠베하 |
낮은 푸코실화를 갖는 항-her2 항체를 이용한 신규한 치료적 처리
|
KR102268351B1
(ko)
|
2012-07-25 |
2021-06-22 |
셀덱스 쎄라퓨틱스, 인크. |
항-kit 항체 및 그의 용도
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
MX365382B
(es)
|
2012-08-07 |
2019-05-31 |
Roche Glycart Ag |
Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
|
EP2888279A1
(en)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
EP2892558B1
(en)
|
2012-09-07 |
2019-04-10 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
TWI606066B
(zh)
|
2012-09-27 |
2017-11-21 |
中外製藥股份有限公司 |
FGFR3 Fusion Gene and Its Targeted Medicine
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
ES2782248T3
(es)
|
2012-10-19 |
2020-09-11 |
Daiichi Sankyo Co Ltd |
Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
|
RU2017137740A
(ru)
|
2012-11-01 |
2019-02-11 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
CN104797599A
(zh)
|
2012-11-05 |
2015-07-22 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
SG11201502538TA
(en)
|
2012-11-08 |
2015-05-28 |
Hoffmann La Roche |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
CA2890669A1
(en)
|
2012-11-13 |
2014-05-22 |
Genetech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
EP2733153A1
(en)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the preparation of immunoconjugates and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
EP2925350B1
(en)
|
2012-12-03 |
2019-01-30 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
JP6306605B2
(ja)
|
2012-12-05 |
2018-04-04 |
ノバルティス アーゲー |
Epoを標的とする抗体のための組成物および方法
|
JP6310397B2
(ja)
|
2012-12-06 |
2018-04-11 |
国立大学法人金沢大学 |
中皮腫の治療方法
|
JP6224619B2
(ja)
|
2012-12-07 |
2017-11-01 |
協和発酵キリン株式会社 |
抗folr1抗体
|
EP3514175A1
(fr)
|
2012-12-17 |
2019-07-24 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
|
CN104884474A
(zh)
|
2012-12-21 |
2015-09-02 |
弗·哈夫曼-拉罗切有限公司 |
包含i类mhc的二硫键连接多价多功能蛋白质
|
EP4119947A1
(en)
|
2012-12-21 |
2023-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
US9550986B2
(en)
|
2012-12-21 |
2017-01-24 |
Abbvie Inc. |
High-throughput antibody humanization
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
EP2938637A2
(en)
|
2012-12-28 |
2015-11-04 |
AbbVie Inc. |
Multivalent binding protein compositions
|
AU2013370171B2
(en)
|
2012-12-28 |
2018-09-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
KR20220156667A
(ko)
|
2013-01-10 |
2022-11-25 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
EP2943511B1
(en)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116596A1
(en)
|
2013-01-22 |
2014-07-31 |
Abbvie, Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
EA201591465A1
(ru)
|
2013-02-08 |
2015-12-30 |
АйАрЭм ЭлЭлСи |
Специфичные участки для модификации антител для получения иммуноконъюгатов
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
EA031537B1
(ru)
|
2013-02-08 |
2019-01-31 |
Новартис Аг |
Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
EP2956482B1
(en)
|
2013-02-14 |
2017-06-28 |
Innate Pharma |
Treatment of peripheral t cell lymphoma
|
EP3521312B1
(en)
|
2013-02-20 |
2021-04-07 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
US9328134B2
(en)
|
2013-02-22 |
2016-05-03 |
Amgen Inc. |
Carbohydrate phosphonate derivatives as modulators of glycosylation
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
KR20150143458A
(ko)
|
2013-03-06 |
2015-12-23 |
메리맥 파마슈티컬즈, 인크. |
항-C-MET 탠덤 Fc 이중특이적 항체
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
WO2014142117A1
(ja)
|
2013-03-12 |
2014-09-18 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
CA2906417C
(en)
|
2013-03-14 |
2022-06-21 |
Robert Ziemann |
Hcv core lipid binding domain monoclonal antibodies
|
BR112015022019A2
(pt)
|
2013-03-14 |
2017-08-29 |
Genentech Inc |
Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
CN105209616A
(zh)
|
2013-03-14 |
2015-12-30 |
雅培制药有限公司 |
用于改进的抗体检测的hcv ns3重组抗原及其突变体
|
CN105143258B
(zh)
|
2013-03-15 |
2020-06-23 |
Ac免疫有限公司 |
抗Tau抗体和使用方法
|
ES2885696T3
(es)
|
2013-03-15 |
2021-12-15 |
Xencor Inc |
Proteínas heterodiméricas
|
EA201591559A1
(ru)
|
2013-03-15 |
2016-03-31 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Терапевтические пептиды
|
MY176706A
(en)
|
2013-03-15 |
2020-08-19 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗gd2抗体
|
WO2014145907A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Targeting t cells with heterodimeric proteins
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
EP3514178A1
(en)
|
2013-03-15 |
2019-07-24 |
Novartis AG |
Antibody drug conjugates
|
EP2970464B1
(en)
|
2013-03-15 |
2020-05-06 |
GlaxoSmithKline Intellectual Property Development Limited |
Anti-lag-3 binding proteins
|
SG10201706210WA
(en)
|
2013-03-15 |
2017-09-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
WO2014144865A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
CA2903587C
(en)
|
2013-03-15 |
2021-09-28 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
JP2016516800A
(ja)
|
2013-04-22 |
2016-06-09 |
グリコトープ ゲーエムベーハー |
フコシル化が少ない抗egfr抗体による抗がん処置
|
JP2016528168A
(ja)
|
2013-04-29 |
2016-09-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
FcRn結合が無効となった抗IGF−1R抗体及び血管性眼疾患の処置におけるそれらの使用
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
EP2992010B1
(en)
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
CA2908743A1
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
KR20160015286A
(ko)
|
2013-05-31 |
2016-02-12 |
제넨테크, 인크. |
항-세포벽 테이코산 항체 및 접합체
|
KR20160015227A
(ko)
|
2013-05-31 |
2016-02-12 |
제넨테크, 인크. |
항-세포벽 테이코산 항체 및 접합체
|
UY35620A
(es)
|
2013-06-21 |
2015-01-30 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
JPWO2014208482A1
(ja)
|
2013-06-24 |
2017-02-23 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
NZ715201A
(en)
|
2013-08-01 |
2021-12-24 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
WO2015020212A1
(ja)
|
2013-08-09 |
2015-02-12 |
東レ株式会社 |
癌の治療及び/又は予防用医薬組成物
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
EP3875487A1
(en)
|
2013-08-12 |
2021-09-08 |
Astrazeneca AB |
Methods for increasing forced expiratory volume in asthmatics using benralizumab
|
JP6803229B2
(ja)
|
2013-08-12 |
2020-12-23 |
アストラゼネカ アクチボラグ |
ベンラリツマブによる喘息症状の改善方法
|
DK3033101T3
(en)
|
2013-08-12 |
2019-04-08 |
Astrazeneca Ab |
PROCEDURES FOR REDUCING EXACT EXERCISE RATES FOR ASTMA USING BENRALIZUMAB
|
AU2014307589A1
(en)
|
2013-08-14 |
2016-02-11 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
WO2015033343A1
(en)
|
2013-09-03 |
2015-03-12 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compositions and methods for expressing recombinant polypeptides
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
US9951123B2
(en)
|
2013-09-30 |
2018-04-24 |
Daiichi Sankyo Company, Limited |
Anti-LPS O11 antibody
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
ES2837392T3
(es)
|
2013-10-02 |
2021-06-30 |
Medimmune Llc |
Anticuerpos anti-influenza A neutralizantes y usos de los mismos
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
WO2015053407A1
(ja)
|
2013-10-08 |
2015-04-16 |
第一三共株式会社 |
抗fgfr2抗体と他剤の組合せ
|
JP6502931B2
(ja)
|
2013-10-11 |
2019-04-17 |
アメリカ合衆国 |
Tem8抗体およびその使用
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
US10081682B2
(en)
|
2013-10-11 |
2018-09-25 |
Oxford Bio Therapeutics Ltd. |
Conjugated antibodies against LY75 for the treatment of cancer
|
WO2015057668A1
(en)
*
|
2013-10-15 |
2015-04-23 |
Medimmune, Llc |
Methods for treating chronic obstructive pulmonary disease using benralizumab
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
JP6715767B2
(ja)
|
2013-10-23 |
2020-07-01 |
ジェネンテック, インコーポレイテッド |
好酸球性疾患の診断及び治療方法
|
EP3066124B1
(en)
|
2013-11-07 |
2021-01-06 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Anticorps allosteriques de la neureguline, dirigés contre her3
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
SI3071597T1
(sl)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti alfa-sinukleinska protitelesa in postopki uporabe
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
TW202043467A
(zh)
|
2013-12-04 |
2020-12-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
BR112016012358A2
(pt)
|
2013-12-06 |
2017-09-26 |
Dana Farber Cancer Inst Inc |
peptídios terapêuticos
|
JP6549143B2
(ja)
|
2013-12-09 |
2019-07-24 |
アラコス インコーポレイテッド |
抗シグレック−8抗体およびその使用の方法
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
CA2933881A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
PT3083694T
(pt)
|
2013-12-20 |
2024-02-01 |
Intervet Int Bv |
Anticorpos murinos caninizados anti-pd-1 canino
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
ES2920677T3
(es)
|
2013-12-24 |
2022-08-08 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-VISTA
|
SI3088419T1
(sl)
|
2013-12-25 |
2019-01-31 |
Daiichi Sankyo Company |
Zdravilni konjugat anti trop2 protitelesa
|
BR112016013347B1
(pt)
|
2013-12-26 |
2023-12-12 |
Mitsubishi Tanabe Pharma Corporation |
Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
|
WO2015099127A1
(ja)
|
2013-12-27 |
2015-07-02 |
中外製薬株式会社 |
Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
BR112016013849A2
(pt)
|
2014-01-03 |
2017-10-10 |
Hoffmann La Roche |
conjugados de anticorpos biespecíficos antihapteno/antirreceptores da barreira hematoencefálica, seus usos, e formulação farmacêutica
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ.ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
MX2016008539A
(es)
|
2014-01-15 |
2016-09-26 |
Hoffmann La Roche |
Variantes de region fc con propiedades de union a receptor fc neonatal (fcrn) modificadas y de union a proteina a mantenidas.
|
FR3016633B1
(fr)
|
2014-01-17 |
2018-04-13 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Immunoglobuline anti-toxine du charbon
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
JP2017505305A
(ja)
|
2014-01-24 |
2017-02-16 |
ジェネンテック, インコーポレイテッド |
抗steap1抗体及びイムノコンジュゲートを使用する方法
|
DK3466976T3
(da)
|
2014-01-31 |
2021-12-13 |
Daiichi Sankyo Co Ltd |
Anti-her2-antistof-lægemiddelkonjugat
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
PL3102230T3
(pl)
|
2014-02-08 |
2021-11-15 |
F.Hoffmann-La Roche Ag |
Sposoby leczenia choroby Alzheimera
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
MX2016010433A
(es)
|
2014-02-12 |
2016-09-22 |
Genentech Inc |
Anticuerpos anti-jagged1 y metodos de uso.
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
TWI558399B
(zh)
|
2014-02-26 |
2016-11-21 |
美國禮來大藥廠 |
癌症之組合療法
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−8関連疾患を処置するための方法および組成物
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
US20150252434A1
(en)
|
2014-03-07 |
2015-09-10 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
BR112016020065A2
(pt)
|
2014-03-12 |
2018-02-20 |
Novartis Ag |
sítios específicos para modificar anticorpos para fazer imunoconjugados
|
US10435694B2
(en)
|
2014-03-14 |
2019-10-08 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
EP3116903A2
(en)
|
2014-03-14 |
2017-01-18 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring nkg2d pathway function against cancers
|
CN106132989B
(zh)
|
2014-03-14 |
2020-06-19 |
先天制药公司 |
具有增加的稳定性的人源化抗体
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
KR20220025946A
(ko)
|
2014-03-21 |
2022-03-03 |
애브비 인코포레이티드 |
항-egfr 항체 및 항체 약물 접합체
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
|
JP6775422B2
(ja)
|
2014-03-28 |
2020-10-28 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd38及びcd3に結合する二重特異性抗体
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
KR101660580B1
(ko)
|
2014-04-02 |
2016-09-28 |
프레스티지 바이오파마 피티이. 엘티디. |
항체의 당 함량 조절을 통한 항체의 제조 방법
|
KR102351755B1
(ko)
|
2014-04-10 |
2022-01-14 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
EP3129055B1
(en)
|
2014-04-11 |
2020-07-01 |
MedImmune, LLC |
Bispecific her2 antibodies
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
EP3141603A4
(en)
|
2014-05-08 |
2017-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
BR112016027222A2
(pt)
|
2014-05-22 |
2018-01-30 |
Genentech Inc |
anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
ES2905777T3
(es)
|
2014-05-30 |
2022-04-12 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
|
EP3970747A3
(en)
|
2014-06-03 |
2022-10-05 |
XBiotech Inc. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
DK3151921T3
(da)
|
2014-06-06 |
2019-12-02 |
Bristol Myers Squibb Co |
Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
|
EP3154585B1
(en)
|
2014-06-11 |
2022-02-23 |
Kathy A. Green |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
KR20170010785A
(ko)
|
2014-06-11 |
2017-02-01 |
제넨테크, 인크. |
항-lgr5 항체 및 이의 용도
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
WO2015197598A2
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
SG11201700446XA
(en)
|
2014-07-21 |
2017-02-27 |
Glykos Finland Oy |
Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
|
WO2016014984A1
(en)
|
2014-07-24 |
2016-01-28 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
KR20240056627A
(ko)
|
2014-08-07 |
2024-04-30 |
노파르티스 아게 |
안지오포이에틴-유사 4 항체 및 사용 방법
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
WO2016024228A1
(en)
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
JP6920194B2
(ja)
|
2014-08-19 |
2021-08-18 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗tigit抗体
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
CA2959141A1
(en)
|
2014-08-28 |
2016-03-03 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
CA2958479A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
BR112017004953A2
(pt)
|
2014-09-17 |
2017-12-05 |
Genentech Inc |
imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
AU2015327819B2
(en)
|
2014-10-03 |
2021-07-01 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
EP3209687A1
(en)
|
2014-10-23 |
2017-08-30 |
Innate Pharma |
Treatment of cancers using anti-nkg2a agents
|
EP3223865A4
(en)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
PL3215528T3
(pl)
|
2014-11-06 |
2020-01-31 |
F.Hoffmann-La Roche Ag |
Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
|
CN107074966A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
JP6831783B2
(ja)
|
2014-11-14 |
2021-02-17 |
ノバルティス アーゲー |
抗体薬物コンジュゲート
|
EP3875481A1
(en)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
CA2966566C
(en)
|
2014-11-20 |
2024-03-19 |
F. Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
MX2017006624A
(es)
|
2014-11-21 |
2017-08-21 |
Bristol Myers Squibb Co |
Anticuerpos contra cd73 y sus usos.
|
PT3221346T
(pt)
|
2014-11-21 |
2020-10-23 |
Bristol Myers Squibb Co |
Anticorpos compreendendo regiões constantes de cadeia pesada modificadas
|
MA41019A
(fr)
|
2014-11-26 |
2021-05-05 |
Xencor Inc |
Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
BR112017011325A2
(pt)
|
2014-12-03 |
2020-07-21 |
Genentech, Inc. |
?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
|
MX2017007231A
(es)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
HUE045216T2
(hu)
|
2014-12-05 |
2019-12-30 |
Hoffmann La Roche |
Anti-CD79B antitestek és alkalmazási eljárások
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
US10858671B2
(en)
|
2014-12-12 |
2020-12-08 |
University Of Copenhagen |
N-glycosylation
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3945096A1
(en)
|
2014-12-19 |
2022-02-02 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
EP3760644A1
(en)
|
2015-01-16 |
2021-01-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
|
WO2016130539A2
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
WO2016134333A1
(en)
|
2015-02-19 |
2016-08-25 |
Compugen Ltd. |
Anti-pvrig antibodies and methods of use
|
KR20170140180A
(ko)
|
2015-02-24 |
2017-12-20 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
EP3072957B1
(en)
|
2015-03-23 |
2019-07-10 |
Lonza Ltd |
Methods for controlling protein glycosylation
|
PT3273992T
(pt)
|
2015-03-23 |
2020-08-21 |
Jounce Therapeutics Inc |
Anticorpos para icos
|
EP3274368A1
(en)
|
2015-03-25 |
2018-01-31 |
THE UNITED STATES OF AMERICA, represented by the S |
Bispecific multivalent fusion proteins
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
AU2016239858B2
(en)
|
2015-04-02 |
2021-07-01 |
Intervet International B.V. |
Antibodies to canine interleukin-4 receptor alpha
|
KR20170132793A
(ko)
|
2015-04-03 |
2017-12-04 |
유레카 쎄라퓨틱스, 인코포레이티드 |
Afp 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
CN107531791B
(zh)
|
2015-04-28 |
2021-09-07 |
田边三菱制药株式会社 |
RGMa结合蛋白质及其使用
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
MA42043A
(fr)
|
2015-05-07 |
2018-03-14 |
Agenus Inc |
Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
JP6587696B2
(ja)
*
|
2015-05-13 |
2019-10-09 |
ズムトール バイオロジクス、インコーポレイテッド |
アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
|
US10526415B2
(en)
|
2015-05-22 |
2020-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor
|
CA2984638A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
US10174121B2
(en)
|
2015-05-29 |
2019-01-08 |
Abbvie, Inc. |
Anti-CD40 antibodies
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
CA2987410A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
PE20180317A1
(es)
|
2015-06-05 |
2018-02-09 |
Genentech Inc |
Anticuerpos anti-tau y metodos de uso
|
WO2016193872A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
SG10202110887PA
(en)
|
2015-06-09 |
2021-11-29 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
TW201709934A
(zh)
|
2015-06-15 |
2017-03-16 |
建南德克公司 |
抗體及免疫結合物
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
IL256079B2
(en)
|
2015-06-16 |
2024-01-01 |
Genentech Inc |
Human antibodies with improved affinity to FCRH5 - and methods of use
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
KR20180012859A
(ko)
|
2015-06-17 |
2018-02-06 |
제넨테크, 인크. |
항-her2 항체 및 이용 방법
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
RU2020124105A
(ru)
|
2015-06-24 |
2020-09-18 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
AU2016286898B2
(en)
|
2015-06-29 |
2022-12-08 |
Daiichi Sankyo Company, Limited |
Method for selectively manufacturing antibody-drug conjugate
|
EP3514174B1
(en)
|
2015-06-29 |
2021-03-31 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
WO2017011517A1
(en)
|
2015-07-16 |
2017-01-19 |
Emory University |
Bis-amines, compositions, and uses related to cxcr4 inhibition
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
PL3331910T3
(pl)
|
2015-08-03 |
2020-05-18 |
Engmab Sàrl |
Przeciwciała monoklonalne przeciwko ludzkiemu antygenowi dojrzewania limfocytów B (BCMA)
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
EP3341415B1
(en)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusine antibodies and uses thereof
|
WO2017037203A1
(en)
|
2015-09-02 |
2017-03-09 |
Immutep S.A.S. |
Anti-LAG-3 Antibodies
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
NZ740067A
(en)
|
2015-09-09 |
2021-07-30 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
BR112018002432A2
(pt)
|
2015-09-18 |
2018-09-18 |
Chugai Pharmaceutical Co Ltd |
anticorpos de ligação à il-8 e usos dos mesmos
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
KR20180083313A
(ko)
|
2015-09-24 |
2018-07-20 |
에이비비트로, 엘엘씨 |
Hiv 항체 조성물 및 사용 방법
|
TWI836305B
(zh)
|
2015-09-24 |
2024-03-21 |
日商第一三共股份有限公司 |
抗garp抗體及其製造方法及用途
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
CR20180149A
(es)
|
2015-10-02 |
2018-04-05 |
Hoffmann La Roche |
Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CN108431038A
(zh)
|
2015-10-06 |
2018-08-21 |
豪夫迈·罗氏有限公司 |
治疗多发性硬化的方法
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
US10968277B2
(en)
|
2015-10-22 |
2021-04-06 |
Jounce Therapeutics, Inc. |
Gene signatures for determining ICOS expression
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
KR102162324B1
(ko)
|
2015-10-30 |
2020-10-07 |
제넨테크, 인크. |
항-HtrA1 항체 및 이의 사용 방법
|
US11236152B2
(en)
|
2015-11-03 |
2022-02-01 |
The United States of America, as represented by the Sectetary, Department of Health and Human Services |
Neutralizing antibodies to HIV-1 GP41 and their use
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
MY189590A
(en)
|
2015-11-18 |
2022-02-18 |
Merck Sharp & Dohme |
Ctla4 binders
|
JO3740B1
(ar)
|
2015-11-18 |
2021-01-31 |
Merck Sharp & Dohme |
روابط pd1/ctla4
|
EP3377531A2
(en)
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme Corp. |
Pd1 and/or lag3 binders
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
SG10201913538VA
(en)
|
2015-11-23 |
2020-02-27 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
US10556948B2
(en)
|
2015-11-30 |
2020-02-11 |
Bristol-Myers Squibb Company |
IP-10 antibodies and their uses
|
WO2017093947A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Antibody cytokine engrafted compositions and methods of use for immunoregulation
|
CA3007030A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CN109069570A
(zh)
|
2015-12-16 |
2018-12-21 |
默沙东公司 |
抗lag3抗体和抗原结合片段
|
SG10201709415WA
(en)
|
2015-12-18 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
US20170198040A1
(en)
|
2015-12-18 |
2017-07-13 |
Novartis Ag |
ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
ES2839408T3
(es)
|
2016-01-13 |
2021-07-05 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un antifolato y un inhibidor de BTK
|
US20190016791A1
(en)
|
2016-01-20 |
2019-01-17 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
MX2018009581A
(es)
|
2016-02-06 |
2019-05-06 |
Epimab Biotherapeutics Inc |
Inmunoglobulina con fabs en tandem y sus usos.
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗vista抗體及片段、其用途及鑑定其之方法
|
US11180546B2
(en)
|
2016-02-17 |
2021-11-23 |
Novartis Ag |
TGFbeta 2 antibodies
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2017148880A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab variants having altered cell death induction
|
CN109476740A
(zh)
|
2016-03-04 |
2019-03-15 |
百时美施贵宝公司 |
利用抗cd73抗体的联合治疗
|
KR20180118673A
(ko)
|
2016-03-15 |
2018-10-31 |
이나뜨 파르마 |
항-mica 항체
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
|
CN108697799A
(zh)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
抗lgr5单克隆抗体的施用
|
WO2017162678A1
(en)
|
2016-03-22 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Humanized anti-claudin-1 antibodies and uses thereof
|
JP6943872B2
(ja)
|
2016-03-25 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
多重全抗体及び抗体複合体化薬物定量化アッセイ
|
US11104739B2
(en)
|
2016-04-14 |
2021-08-31 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CN118108843A
(zh)
|
2016-04-15 |
2024-05-31 |
伊穆奈克斯特股份有限公司 |
抗人vista抗体及其用途
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
US11230591B2
(en)
|
2016-04-20 |
2022-01-25 |
Merck Sharp & Dohme Corp. |
CMV neutralizing antigen binding proteins
|
US11312766B2
(en)
|
2016-04-27 |
2022-04-26 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
TW202208441A
(zh)
|
2016-05-13 |
2022-03-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
CA3024476A1
(en)
|
2016-05-18 |
2017-11-23 |
Genmab B.V. |
Antibodies and methods of use thereof in treatment of infectious disease
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3458479B1
(en)
|
2016-06-08 |
2020-11-04 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109562170B
(zh)
|
2016-06-08 |
2023-01-13 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
BR112018075630A2
(pt)
|
2016-06-08 |
2019-03-19 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de fármaco de anticorpo
|
US20200338209A1
(en)
|
2016-06-08 |
2020-10-29 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
EP3468993A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
DK3468997T3
(da)
|
2016-06-08 |
2023-10-02 |
Xencor Inc |
Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
|
EP3468615A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-egfr antibody drug conjugates
|
CN116059201A
(zh)
|
2016-06-08 |
2023-05-05 |
艾伯维公司 |
抗egfr抗体药物偶联物
|
BR112018075644A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-cd98 e conjugados de anticorpo e fármaco
|
US20190153108A1
(en)
|
2016-06-08 |
2019-05-23 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
WO2017216724A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
CN117683135A
(zh)
|
2016-07-14 |
2024-03-12 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
CA3030834A1
(en)
|
2016-07-15 |
2018-01-18 |
Takeda Pharmaceutical Company Limited |
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
KR102487356B1
(ko)
|
2016-07-29 |
2023-01-12 |
엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 |
종양 관련 대식세포를 표적화하는 항체 및 이의 용도
|
CN109415444B
(zh)
|
2016-07-29 |
2024-03-01 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
AU2017301887A1
(en)
|
2016-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-CD19 antibodies
|
JP2019525934A
(ja)
|
2016-07-29 |
2019-09-12 |
イーライ リリー アンド カンパニー |
癌の治療に使用するためのメレスチニブおよび抗pd−l1または抗pd−1阻害剤を用いた組み合わせ治療
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
WO2018027042A1
(en)
|
2016-08-03 |
2018-02-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
US11773162B2
(en)
|
2016-08-05 |
2023-10-03 |
Allakos, Inc. |
Anti-Siglec-7 antibodies for the treatment of cancer
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
BR112019002579A2
(pt)
|
2016-08-16 |
2019-05-21 |
Epimab Biotherapeutics, Inc. |
anticorpos biespecíficos fab monovalentes, assimétricos e tandem
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
US20190270821A1
(en)
|
2016-09-13 |
2019-09-05 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
FI3528838T3
(fi)
|
2016-09-23 |
2023-10-02 |
Hoffmann La Roche |
IL-13-antagonistien käyttöjä atooppisen ihottuman hoitamiseksi
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
US11072660B2
(en)
|
2016-10-03 |
2021-07-27 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
KR20190066026A
(ko)
|
2016-10-07 |
2019-06-12 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
MX2019004371A
(es)
|
2016-10-13 |
2019-11-18 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
|
KR102649972B1
(ko)
|
2016-10-14 |
2024-03-22 |
젠코어 인코포레이티드 |
IL15/IL15Rα 이종이량체 Fc-융합 단백질
|
CN109863175A
(zh)
|
2016-10-21 |
2019-06-07 |
依奈特制药公司 |
用抗-kir3dl2药剂进行的治疗
|
US11186635B2
(en)
|
2016-10-25 |
2021-11-30 |
Institut National De La Santé Et De La Recherché Médical (Inserm) |
Monoclonal antibodies binding to the CD160 transmembrane isoform
|
MX2019004779A
(es)
|
2016-10-28 |
2019-08-12 |
Toray Industries |
Composicion farmaceutica para tratamiento y/o prevencion de cancer.
|
CN110352073A
(zh)
|
2016-10-28 |
2019-10-18 |
机敏医药股份有限公司 |
针对timp-2的抗体用于改善肾功能的用途
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
SG11201903693QA
(en)
|
2016-11-01 |
2019-05-30 |
Genmab Bv |
Polypeptide variants and uses thereof
|
CA3039992A1
(en)
|
2016-11-02 |
2018-05-11 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
JP7267914B2
(ja)
|
2016-11-02 |
2023-05-02 |
エンクマフ エスアーエールエル |
Bcma及びcd3に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
|
MX2019004775A
(es)
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
JP2020500020A
(ja)
|
2016-11-14 |
2020-01-09 |
ノバルティス アーゲー |
融合誘導性タンパク質minionに関連する組成物、方法、および治療上の使用
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
CN109963562A
(zh)
|
2016-11-16 |
2019-07-02 |
伊莱利利公司 |
用于具有外显子14跳读突变或外显子14跳读表型的癌症的组合疗法
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
WO2018098370A1
(en)
|
2016-11-23 |
2018-05-31 |
Immunoah Therapeutics, Inc. |
4-1bb binding proteins and uses thereof
|
WO2018098363A2
(en)
|
2016-11-23 |
2018-05-31 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
TW201825119A
(zh)
|
2016-11-30 |
2018-07-16 |
日商協和醱酵麒麟有限公司 |
使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
KR102587130B1
(ko)
|
2016-12-07 |
2023-10-11 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
CN117820467A
(zh)
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
WO2018110515A1
(ja)
|
2016-12-12 |
2018-06-21 |
第一三共株式会社 |
抗体-薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
WO2018111890A1
(en)
|
2016-12-12 |
2018-06-21 |
Genentech, Inc. |
Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
|
WO2018117237A1
(ja)
|
2016-12-22 |
2018-06-28 |
第一三共株式会社 |
抗cd3抗体及び該抗体を含む分子
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
JP7139332B2
(ja)
|
2016-12-23 |
2022-09-20 |
ノバルティス アーゲー |
第xi因子抗体および使用方法
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
KR20190104048A
(ko)
|
2017-01-06 |
2019-09-05 |
이오반스 바이오테라퓨틱스, 인크. |
종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
|
EP3523332B1
(en)
|
2017-01-06 |
2021-12-29 |
Eutilex Co., Ltd. |
Anti-human 4-1 bb antibodies and use thereof
|
JP2020503351A
(ja)
|
2017-01-06 |
2020-01-30 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
KR102537651B1
(ko)
|
2017-01-17 |
2023-05-26 |
다이이찌 산쿄 가부시키가이샤 |
항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
|
EP3574918A4
(en)
|
2017-01-24 |
2021-03-03 |
Kyowa Kirin Co., Ltd. |
THERAPEUTIC OR PROPHYLACTIC AND TREATMENT OR PREVENTION PROCEDURES FOR RADIATION DISEASE
|
SG10201912368XA
(en)
|
2017-02-07 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Anti-gprc5d antibody and molecule comprising the antibody
|
CA3052911A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
BR112019015900A2
(pt)
|
2017-02-10 |
2020-04-07 |
Genmab B.V. |
polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
|
WO2018148660A1
(en)
|
2017-02-10 |
2018-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
CR20190387A
(es)
|
2017-02-10 |
2019-09-25 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
MX2019009619A
(es)
|
2017-02-10 |
2019-12-18 |
Eutilex Co Ltd |
Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
WO2018151821A1
(en)
|
2017-02-17 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
JP2020509037A
(ja)
|
2017-02-28 |
2020-03-26 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
ワクチンに対する免疫応答を増強するための、adccが増強された抗ctla−4抗体の使用
|
CA3053749A1
(en)
|
2017-02-28 |
2018-09-07 |
Kinki University |
Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
|
TW201837467A
(zh)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
EP3589654A1
(en)
|
2017-03-02 |
2020-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
JP6430082B1
(ja)
|
2017-03-02 |
2018-11-28 |
学校法人 聖マリアンナ医科大学 |
低用量抗ccr4抗体を用いたhtlv−1関連脊髄症の予防または治療剤
|
JP7227151B2
(ja)
|
2017-03-22 |
2023-02-21 |
ジェネンテック, インコーポレイテッド |
眼障害の治療のために最適化された抗体組成物
|
KR20240014600A
(ko)
|
2017-03-24 |
2024-02-01 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
CN110650976B
(zh)
|
2017-04-13 |
2024-04-19 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
EP3610042A1
(en)
|
2017-04-14 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
KR102663596B1
(ko)
|
2017-04-26 |
2024-05-10 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
MX2019012793A
(es)
|
2017-04-27 |
2020-02-13 |
Tesaro Inc |
Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
CN110831628A
(zh)
|
2017-05-05 |
2020-02-21 |
爱乐科斯公司 |
用于治疗过敏性眼病的方法和组合物
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
US11116835B2
(en)
|
2017-05-10 |
2021-09-14 |
Fred Hutchinson Cancer Research Center |
Epstein Barr virus antibodies, vaccines, and uses of the same
|
AU2018266202A1
(en)
|
2017-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
SG10202112636SA
(en)
|
2017-05-16 |
2021-12-30 |
Five Prime Therapeutics Inc |
Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
MX2019014023A
(es)
|
2017-05-24 |
2020-02-17 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
|
KR20220167342A
(ko)
|
2017-05-25 |
2022-12-20 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
CA3064333A1
(en)
|
2017-05-29 |
2018-12-06 |
Gamamabs Pharma |
Cancer-associated immunosuppression inhibitor
|
CA3064331A1
(en)
|
2017-06-01 |
2018-12-06 |
Compugen Ltd. |
Triple combination antibody therapies
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CA3067603A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
TWI820031B
(zh)
|
2017-07-11 |
2023-11-01 |
美商坎伯斯治療有限責任公司 |
結合人類cd137之促效劑抗體及其用途
|
JP7197865B2
(ja)
|
2017-07-18 |
2022-12-28 |
協和キリン株式会社 |
抗ヒトccr1モノクローナル抗体
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
WO2019023347A1
(en)
|
2017-07-26 |
2019-01-31 |
Forty Seven, Inc. |
ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
|
CA3071234A1
(en)
|
2017-07-27 |
2019-01-31 |
Daiichi Sankyo Company, Limited |
Anti-cd147 antibody
|
CN110944667A
(zh)
|
2017-08-23 |
2020-03-31 |
第一三共株式会社 |
抗体-药物缀合物制剂及其冻干
|
BR112020003533A2
(pt)
|
2017-08-25 |
2020-11-17 |
Five Prime Therapeutics, Inc. |
anticorpos b7-h4 e métodos de uso dos mesmos
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
CA3073924C
(en)
|
2017-08-31 |
2023-10-17 |
Daiichi Sankyo Company, Limited |
Improved method for producing antibody-drug conjugate
|
EP3684413A1
(en)
|
2017-09-20 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
CN117003875A
(zh)
|
2017-09-29 |
2023-11-07 |
第一三共株式会社 |
抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
|
AU2018345539A1
(en)
|
2017-10-03 |
2020-04-16 |
Editas Medicine, Inc. |
HPV-specific binding molecules
|
WO2019070013A1
(ja)
|
2017-10-05 |
2019-04-11 |
第一三共株式会社 |
細胞傷害性t細胞枯渇用組成物
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
US11912754B2
(en)
|
2017-10-12 |
2024-02-27 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
EP3708589A4
(en)
|
2017-11-08 |
2021-08-11 |
Kyowa Kirin Co., Ltd. |
BIS SPECIFIC ANTIBODY BINDING TO CD40 AND EPCAM
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
US20200325232A1
(en)
|
2017-11-21 |
2020-10-15 |
Innate Pharma |
Multispecific antigen binding proteins
|
CA3083210A1
(en)
|
2017-11-22 |
2018-11-20 |
Novartis Ag |
Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
|
EP3717516A1
(en)
|
2017-12-01 |
2020-10-07 |
Pfizer Inc |
Anti-cxcr5 antibodies and compositions and uses thereof
|
EP3717510A2
(en)
|
2017-12-01 |
2020-10-07 |
Novartis AG |
Polyomavirus neutralizing antibodies
|
US20210171598A1
(en)
|
2017-12-01 |
2021-06-10 |
University Of Copenhagen |
Peptide hormone with one or more o-glycans
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
CA3085765A1
(en)
|
2017-12-15 |
2019-06-20 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
KR20200103706A
(ko)
|
2017-12-22 |
2020-09-02 |
조운스 테라퓨틱스, 인크. |
Lilrb2에 대한 항체
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
TW201930350A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
CN112041341B
(zh)
|
2017-12-28 |
2024-05-24 |
机敏医药股份有限公司 |
Ccl14的抗体和检测
|
US11976109B2
(en)
|
2018-01-02 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
BR112020013663A2
(pt)
|
2018-01-05 |
2020-12-01 |
Ac Immune Sa |
moléculas de ligação ao tdp-43 dobrado incorretamente
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
US20200339686A1
(en)
|
2018-01-16 |
2020-10-29 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
RS63812B1
(sr)
|
2018-01-26 |
2023-01-31 |
Hoffmann La Roche |
Il-22 fc kompozicije i postupci primene
|
EP3743437A1
(en)
|
2018-01-26 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Il-22 fc fusion proteins and methods of use
|
CN111601825B
(zh)
|
2018-02-01 |
2022-11-29 |
信达生物制药(苏州)有限公司 |
全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
WO2019152810A1
(en)
|
2018-02-02 |
2019-08-08 |
Bio-Techne Corporation |
Compounds that modulate the interaction of vista and vsig3 and methods of making and using
|
EP3749361A1
(en)
|
2018-02-08 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen-binding molecules and methods of use
|
KR20230142806A
(ko)
|
2018-02-09 |
2023-10-11 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
WO2019158645A1
(en)
|
2018-02-14 |
2019-08-22 |
Abba Therapeutics Ag |
Anti-human pd-l2 antibodies
|
WO2019165140A1
(en)
|
2018-02-21 |
2019-08-29 |
Genentech, Inc. |
DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
|
MX2020008736A
(es)
|
2018-02-21 |
2020-12-07 |
Five Prime Therapeutics Inc |
Formulaciones de anticuerpos b7-h4.
|
EP3755713A1
(en)
|
2018-02-21 |
2020-12-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2019165075A1
(en)
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody dosing regimens
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
WO2019172165A1
(ja)
|
2018-03-05 |
2019-09-12 |
学校法人埼玉医科大学 |
異所性骨化の治療又は予防のための医薬組成物
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
WO2019174617A1
(en)
|
2018-03-14 |
2019-09-19 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
CA3092589A1
(en)
|
2018-03-21 |
2019-09-26 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
WO2019183551A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
CN111936164A
(zh)
|
2018-03-30 |
2020-11-13 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
SG11202009284TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cell receptors and engineered cells expressing same
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
MA52485A
(fr)
|
2018-05-03 |
2021-03-10 |
Genmab Bv |
Combinaisons de variants d'anticorps et utilisations associées
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
CA3100018A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
JP7460609B2
(ja)
|
2018-05-14 |
2024-04-02 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なインターロイキン-2ポリペプチド及びその使用方法
|
JP2021524740A
(ja)
|
2018-05-18 |
2021-09-16 |
グリコトープ ゲーエムベーハー |
抗muc1抗体
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
BR112020024061A2
(pt)
|
2018-05-28 |
2021-02-17 |
Daiichi Sankyo Company, Limited |
agente terapêutico para câncer com her2 mutado
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
WO2019230869A1
(ja)
|
2018-05-31 |
2019-12-05 |
第一三共株式会社 |
抗ヒトtlr7抗体
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
BR112020023505A2
(pt)
|
2018-06-01 |
2021-03-30 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Composições e usos das mesmas para tratamento de doença ou condição
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
WO2019234576A1
(en)
|
2018-06-03 |
2019-12-12 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
US11993661B2
(en)
|
2018-06-18 |
2024-05-28 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
TW202020158A
(zh)
|
2018-06-26 |
2020-06-01 |
日商協和麒麟股份有限公司 |
與細胞黏著分子3 結合之抗體
|
WO2020004490A1
(ja)
|
2018-06-26 |
2020-01-02 |
協和キリン株式会社 |
コンドロイチン硫酸プロテオグリカン-5に結合する抗体
|
WO2020010079A2
(en)
|
2018-07-02 |
2020-01-09 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
PE20211604A1
(es)
|
2018-07-09 |
2021-08-23 |
Five Prime Therapeutics Inc |
Anticuerpos de union a ilt4
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
KR20210031722A
(ko)
|
2018-07-11 |
2021-03-22 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
CR20210081A
(es)
|
2018-07-13 |
2021-06-24 |
Genmab As |
Variantes de anticuerpos anti-cd38 y sus usos.
|
MA53123A
(fr)
|
2018-07-13 |
2021-05-19 |
Genmab As |
Thérapie à médiation par trogocytose utilisant des anticorps cd38
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
SG11202100373VA
(en)
|
2018-07-20 |
2021-02-25 |
Surface Oncology Inc |
Anti-cd112r compositions and methods
|
KR20210038904A
(ko)
|
2018-07-25 |
2021-04-08 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘쥬게이트의 효과적인 제조 방법
|
SG11202100947SA
(en)
|
2018-07-31 |
2021-03-30 |
Daiichi Sankyo Co Ltd |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
AU2019315226A1
(en)
|
2018-08-03 |
2021-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
BR112021001750A2
(pt)
|
2018-08-06 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
composição farmacêutica
|
US20200047085A1
(en)
|
2018-08-09 |
2020-02-13 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
BR112021002037A2
(pt)
|
2018-08-10 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação de antígeno anti-cd137 e uso da mesma
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
KR20210057053A
(ko)
|
2018-08-23 |
2021-05-20 |
씨젠 인크. |
항-tigit 항체
|
JP7481255B2
(ja)
|
2018-08-23 |
2024-05-10 |
第一三共株式会社 |
抗体薬物複合体の感受性マーカー
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
MX2021002190A
(es)
|
2018-08-31 |
2021-05-14 |
Regeneron Pharma |
Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
US20220098613A1
(en)
|
2018-09-12 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
CA3109366A1
(en)
|
2018-09-13 |
2020-03-19 |
The Board Of Regents Of The University Of Texas System |
Novel lilrb4 antibodies and uses thereof
|
WO2020058372A1
(en)
|
2018-09-19 |
2020-03-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
BR112021005246A2
(pt)
|
2018-09-20 |
2021-06-15 |
Daiichi Sankyo Company, Limited |
agente terapêutico, e, método de tratamento para câncer
|
EP3852524B1
(en)
|
2018-09-20 |
2023-06-28 |
Iovance Biotherapeutics, Inc. |
Expansion of tils from cryopreserved tumor samples
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
TW202028467A
(zh)
|
2018-09-28 |
2020-08-01 |
日商協和麒麟股份有限公司 |
抗體組合物
|
WO2020072821A2
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
SG11202102875YA
(en)
|
2018-10-05 |
2021-04-29 |
Five Prime Therapeutics Inc |
Anti-fgfr2 antibody formulations
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
CN113166242A
(zh)
|
2018-10-15 |
2021-07-23 |
戊瑞治疗有限公司 |
用于癌症的组合疗法
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
CA3118634A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
US20220025058A1
(en)
|
2018-11-06 |
2022-01-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
SG11202104864QA
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
AU2019379418A1
(en)
|
2018-11-14 |
2021-06-03 |
Daiichi Sankyo Company, Limited |
Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
|
KR20210101235A
(ko)
|
2018-11-16 |
2021-08-18 |
메모리얼 슬로안 케터링 캔서 센터 |
뮤신-16에 대한 항체 및 이의 사용 방법
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2020117952A2
(en)
|
2018-12-05 |
2020-06-11 |
Genentech, Inc. |
Diagnostic methods and compositions for cancer immunotherapy
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
WO2020122034A1
(ja)
|
2018-12-11 |
2020-06-18 |
第一三共株式会社 |
抗体-薬物コンジュゲートとparp阻害剤の組み合わせ
|
JP2022516408A
(ja)
|
2018-12-14 |
2022-02-28 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
単離されたMHC由来ヒトペプチドおよびCD8+CD45RClowTregの抑制機能を刺激し、かつ活性化するためのその使用
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
WO2020132214A2
(en)
|
2018-12-20 |
2020-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
改変抗体fcおよび使用方法
|
KR20210107721A
(ko)
|
2018-12-21 |
2021-09-01 |
23앤드미 인코포레이티드 |
항-il-36 항체 및 이의 사용 방법
|
TW202038957A
(zh)
|
2018-12-21 |
2020-11-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與激酶抑制劑之組合
|
MX2021007769A
(es)
|
2018-12-26 |
2021-09-23 |
Xilio Dev Inc |
Proteínas de unión anti-ctla4 enmascaradas activables.
|
WO2020138487A1
(ja)
|
2018-12-28 |
2020-07-02 |
協和キリン株式会社 |
TfRに結合するバイスペシフィック抗体
|
CN113272327A
(zh)
|
2018-12-30 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
抗兔cd19抗体及其使用方法
|
US20220112557A1
(en)
|
2019-01-10 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
CA3124837A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
CN109762067B
(zh)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|
BR112021014106A2
(pt)
|
2019-01-22 |
2021-10-13 |
Bristol-Myers Squibb Company |
Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
|
BR112021014574A2
(pt)
|
2019-01-23 |
2021-10-05 |
Encefa |
Competidores cd31 e usos dos mesmos
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
MA54863A
(fr)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
AU2020233284A1
(en)
|
2019-03-01 |
2021-09-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
MX2021010390A
(es)
|
2019-03-01 |
2021-11-17 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a enpp3 y cd3.
|
KR20210138588A
(ko)
|
2019-03-08 |
2021-11-19 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
MA55296A
(fr)
|
2019-03-14 |
2022-03-23 |
Hoffmann La Roche |
Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
WO2020196474A1
(ja)
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
CA3191804A1
(en)
|
2019-03-25 |
2020-10-01 |
Daiichi Sankyo Company, Limited |
Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
|
WO2020196712A1
(ja)
|
2019-03-27 |
2020-10-01 |
第一三共株式会社 |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
US20220193237A1
(en)
|
2019-04-18 |
2022-06-23 |
Bristol-Myers Squibb Company |
Ipilimumab variants with enhanced specificity for binding at low ph
|
EP3957325A4
(en)
|
2019-04-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
EP3962523A2
(en)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
JP2022532217A
(ja)
|
2019-05-14 |
2022-07-13 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
分離部分及びその使用方法
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20220220216A1
(en)
|
2019-05-15 |
2022-07-14 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody binding to cd40 and gpc3
|
WO2020230899A1
(ja)
|
2019-05-15 |
2020-11-19 |
協和キリン株式会社 |
Cd40とfapに結合するバイスペシフィック抗体
|
WO2020236841A2
(en)
|
2019-05-20 |
2020-11-26 |
Novartis Ag |
Antibody drug conjugates having linkers comprising hydrophilic groups
|
EP3972997A1
(en)
|
2019-05-20 |
2022-03-30 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Novel anti-cd25 antibodies
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
US20210139585A1
(en)
|
2019-05-21 |
2021-05-13 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
CA3140142A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
WO2020234473A1
(en)
|
2019-05-23 |
2020-11-26 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
BR112021023901A2
(pt)
|
2019-05-29 |
2022-01-18 |
Daiichi Sankyo Co Ltd |
Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
|
JOP20210326A1
(ar)
|
2019-06-12 |
2023-01-30 |
Novartis Ag |
أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
|
AU2020308053A1
(en)
|
2019-06-26 |
2022-01-20 |
Glaxosmithkline Intellectual Property Development Limited |
IL1RAP binding proteins
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
CN114341187A
(zh)
|
2019-07-12 |
2022-04-12 |
中外制药株式会社 |
抗突变型fgfr3抗体及其用途
|
CA3145345A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies against canine ctla-4
|
CN114174336A
(zh)
|
2019-07-15 |
2022-03-11 |
英特维特国际股份有限公司 |
针对人和犬ctla-4的犬源化抗体
|
EP3999540A1
(en)
|
2019-07-16 |
2022-05-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity for cd38 and uses thereof
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
JPWO2021020282A1
(sh)
|
2019-07-26 |
2021-02-04 |
|
|
BR112022001575A2
(pt)
|
2019-07-29 |
2022-04-19 |
Compugen Ltd |
Formulações de anticorpos anti-pvrig e usos dos mesmos
|
WO2021024133A2
(en)
|
2019-08-06 |
2021-02-11 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmacuetical compositions and related methods
|
CA3148740A1
(en)
|
2019-08-06 |
2021-02-11 |
Aprinoia Therapeutics Limited |
Antibodies that bind to pathological tau species and uses thereof
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
AU2020350689A1
(en)
|
2019-09-19 |
2022-03-31 |
Bristol-Myers Squibb Company |
Antibodies binding to VISTA at acidic pH
|
TW202126699A
(zh)
|
2019-09-20 |
2021-07-16 |
美商建南德克公司 |
用於抗類胰蛋白酶抗體之投藥
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
TW202126688A
(zh)
|
2019-09-27 |
2021-07-16 |
瑞典商阿斯特捷利康公司 |
使用貝那利珠單抗治療遲發性氣喘之方法
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
EP4045090A1
(en)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2021091605A1
(en)
|
2019-11-04 |
2021-05-14 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
WO2021100794A1
(ja)
|
2019-11-20 |
2021-05-27 |
中外製薬株式会社 |
抗体含有製剤
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
BR112022010627A2
(pt)
|
2019-12-06 |
2022-08-16 |
Juno Therapeutics Inc |
Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
WO2021123092A1
(en)
|
2019-12-20 |
2021-06-24 |
Intervet International B.V. |
Bispecific caninized antibodies for treating atopic dermatitis
|
WO2021127414A1
(en)
|
2019-12-20 |
2021-06-24 |
Bristol-Myers Squibb Company |
Use of fucosylation inhibitor for producing afucosylated antibody
|
CA3162031A1
(en)
|
2019-12-20 |
2021-06-24 |
Mohamad Morsey |
Canine interleukin-4 receptor alpha antibodies
|
AR120898A1
(es)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
Agente para tratar o prevenir neuromielitis óptica en fase aguda
|
CN110964090B
(zh)
*
|
2019-12-26 |
2021-02-19 |
江南大学 |
一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
BR112022011723A2
(pt)
|
2019-12-27 |
2022-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-ctla-4 e uso do mesmo
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
AR121065A1
(es)
|
2020-01-15 |
2022-04-13 |
Univ Osaka |
Agente para tratar o prevenir demencia
|
CA3165660A1
(en)
|
2020-01-16 |
2021-07-22 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
TW202140561A
(zh)
|
2020-02-14 |
2021-11-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
EP4103285A2
(en)
|
2020-02-14 |
2022-12-21 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
EP4093762A1
(en)
|
2020-02-20 |
2022-11-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
EP4110816A1
(en)
|
2020-02-27 |
2023-01-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antibodies binding il4r and uses thereof
|
JP2023516941A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト、多重特異性抗体及びその使用
|
KR20220148209A
(ko)
|
2020-02-28 |
2022-11-04 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물 및 그 용도
|
BR112022018157A2
(pt)
|
2020-03-12 |
2022-10-25 |
Toray Industries |
Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
|
EP4119160A4
(en)
|
2020-03-12 |
2024-04-03 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
JPWO2021182570A1
(sh)
|
2020-03-12 |
2021-09-16 |
|
|
WO2021182571A1
(ja)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
KR20220153615A
(ko)
|
2020-03-12 |
2022-11-18 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
KR20220152262A
(ko)
|
2020-03-13 |
2022-11-15 |
제넨테크, 인크. |
항-인터루킨-33 항체 및 이의 용도
|
AU2021236660A1
(en)
|
2020-03-19 |
2022-08-18 |
Genentech, Inc. |
Isoform-selective anti-TGF-beta antibodies and methods of use
|
IL296673A
(en)
|
2020-03-23 |
2022-11-01 |
Bristol Myers Squibb Co |
Anti-ccr8 antibodies for cancer treatment
|
BR112022018847A2
(pt)
|
2020-03-24 |
2022-11-22 |
Genentech Inc |
Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
IL296514A
(en)
|
2020-03-30 |
2022-11-01 |
Univ Mie |
Bispecific antibody
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
CA3179369A1
(en)
|
2020-04-01 |
2021-10-07 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
JP2023522930A
(ja)
|
2020-04-24 |
2023-06-01 |
ジェネンテック, インコーポレイテッド |
抗CD79b免疫抱合体の使用方法
|
CA3172880A1
(en)
|
2020-04-27 |
2021-11-04 |
Sotirios Tsimikas |
Isoform-independent antibodies to lipoprotein(a)
|
KR20230002261A
(ko)
|
2020-04-28 |
2023-01-05 |
더 락커펠러 유니버시티 |
항-sars-cov-2 중화 항체 및 이의 사용 방법
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
KR20230017207A
(ko)
|
2020-04-30 |
2023-02-03 |
사이로파 비.브이. |
항-cd103 항체
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁(苏州)生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
KR20230010691A
(ko)
|
2020-05-12 |
2023-01-19 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
St2 항원 결합 단백질
|
KR20230008751A
(ko)
|
2020-05-12 |
2023-01-16 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
피부 t-세포 림프종 및 tfh 유래된 림프종을 치료하는 신규한 방법
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
US20210355196A1
(en)
|
2020-05-17 |
2021-11-18 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
AU2021282179A1
(en)
|
2020-05-26 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
AU2021281417A1
(en)
|
2020-05-29 |
2022-12-08 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
MX2022015376A
(es)
|
2020-06-02 |
2023-04-14 |
Dynamicure Biotechnology Llc |
Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
|
EP4161960A1
(en)
|
2020-06-03 |
2023-04-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗il-36抗体およびその使用方法
|
WO2021259227A1
(zh)
|
2020-06-23 |
2021-12-30 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
TW202216759A
(zh)
|
2020-06-25 |
2022-05-01 |
美商默沙東藥廠 |
靶向絲胺酸413經磷酸化之tau之高親和力抗體
|
KR20230030632A
(ko)
|
2020-06-30 |
2023-03-06 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
항-cd70 항체 및 이의 적용
|
TW202216212A
(zh)
|
2020-07-17 |
2022-05-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物之製造方法
|
CN115884794A
(zh)
|
2020-07-20 |
2023-03-31 |
第一三共株式会社 |
抗her2抗体药物缀合物与her二聚化抑制剂的组合
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2022026763A1
(en)
|
2020-07-29 |
2022-02-03 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
IL300260A
(en)
|
2020-08-07 |
2023-03-01 |
Genentech Inc |
FLT3 ligand fusion proteins and methods of use
|
BR112023002234A2
(pt)
|
2020-08-10 |
2023-03-07 |
Astrazeneca Uk Ltd |
Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
|
KR20230050389A
(ko)
|
2020-08-13 |
2023-04-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-2를 관심 표적 세포로 재지시하는 방법
|
CN116615452A
(zh)
|
2020-08-14 |
2023-08-18 |
Ac免疫有限公司 |
人源化抗tdp-43结合分子及其用途
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
JP6799831B1
(ja)
|
2020-09-01 |
2020-12-16 |
中外製薬株式会社 |
Il−31アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び/又は治療用医薬組成物
|
CA3192323A1
(en)
|
2020-09-14 |
2022-03-17 |
Julie MACOIN |
Antibodies that bind to il1rap and uses thereof
|
AU2021352981A1
(en)
|
2020-09-30 |
2023-06-08 |
Dren Bio, Inc. |
Anti-cd94 antibodies and methods of use thereof
|
US20230365680A1
(en)
|
2020-09-30 |
2023-11-16 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
TW202231292A
(zh)
|
2020-10-13 |
2022-08-16 |
美商健生生物科技公司 |
用於調節分化簇iv及/或viii的經生物工程改造之t細胞介導之免疫力、材料、及其他方法
|
EP4228764A1
(en)
|
2020-10-14 |
2023-08-23 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
CA3190782A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
|
EP4232475A1
(en)
|
2020-10-20 |
2023-08-30 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
EP4232822A2
(en)
|
2020-10-26 |
2023-08-30 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
WO2022098628A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
US20220162329A1
(en)
|
2020-11-04 |
2022-05-26 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
JP2023548064A
(ja)
|
2020-11-04 |
2023-11-15 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体及び抗cd79b抗体薬物コンジュゲートによる処置のための投与
|
US20240002513A1
(en)
|
2020-11-06 |
2024-01-04 |
Bristol-Myers Squibb Company |
Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy
|
JP2023548529A
(ja)
|
2020-11-06 |
2023-11-17 |
ノバルティス アーゲー |
Cd19結合分子及びその使用
|
EP4240494A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022102634A1
(ja)
|
2020-11-11 |
2022-05-19 |
第一三共株式会社 |
抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ
|
US20230398230A1
(en)
|
2020-11-12 |
2023-12-14 |
Daiichi Sankyo Company, Limited |
Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
|
CA3199006A1
(en)
|
2020-11-20 |
2022-05-27 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-cd25 antibodies
|
JP2024504547A
(ja)
|
2020-11-20 |
2024-02-01 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
抗cd25抗体
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
EP4259164A1
(en)
|
2020-12-11 |
2023-10-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
US11479610B2
(en)
|
2020-12-23 |
2022-10-25 |
Cantargia Ab |
Anti-IL1RAP antibody
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
CN114685669A
(zh)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
结合trop2的抗体及其用途
|
CA3203382A1
(en)
|
2020-12-31 |
2022-07-07 |
Adrian Emanual Wells |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
EP4276111A1
(en)
|
2021-01-08 |
2023-11-15 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
|
JP2024503396A
(ja)
|
2021-01-08 |
2024-01-25 |
北京韓美薬品有限公司 |
Cd47と特異的に結合する抗体及びその抗原結合フラグメント
|
CN117425500A
(zh)
|
2021-01-13 |
2024-01-19 |
纪念斯隆凯特琳癌症中心 |
抗dll3抗体-药物缀合物
|
AU2022207708A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
US20240076373A1
(en)
|
2021-01-28 |
2024-03-07 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
EP4284516A1
(en)
|
2021-01-28 |
2023-12-06 |
Compugen Ltd. |
Anti-pvrig antibodies formulations and uses thereof
|
AU2022212599A1
(en)
|
2021-01-28 |
2023-08-17 |
Universität Ulm |
Method and means for modulating b-cell mediated immune responses
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
EP4291226A1
(en)
|
2021-02-09 |
2023-12-20 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Antibodies targeting the spike protein of coronaviruses
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
CA3208365A1
(en)
|
2021-02-15 |
2022-08-18 |
Chantal KUHN |
Cell therapy compositions and methods for modulating tgf-b signaling
|
AR124914A1
(es)
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
CN117440832A
(zh)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
包括抗bcma抗体的抗体-药物缀合物
|
CN117279506A
(zh)
|
2021-03-05 |
2023-12-22 |
艾欧凡斯生物治疗公司 |
肿瘤储存及细胞培养组合物
|
US20240141048A1
(en)
|
2021-03-05 |
2024-05-02 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
JP2024518013A
(ja)
|
2021-03-10 |
2024-04-24 |
イミュノウェイク インコーポレイテッド |
免疫調節分子及びその使用
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
MX2023010917A
(es)
|
2021-03-18 |
2023-09-27 |
Medimmune Ltd |
Molecula de union terapeutica que se une a ccr9.
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
US20240175873A1
(en)
|
2021-03-23 |
2024-05-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
TW202305118A
(zh)
|
2021-03-23 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球之cish基因編輯及其在免疫療法中之用途
|
CN117616041A
(zh)
|
2021-03-25 |
2024-02-27 |
当康生物技术有限责任公司 |
抗-igfbp7构建体及其用途
|
TW202305360A
(zh)
|
2021-03-25 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
用於t細胞共培養效力測定及配合細胞療法產品使用的方法及組合物
|
MX2023011310A
(es)
|
2021-03-26 |
2023-10-05 |
Innate Pharma |
Anclajes de citocina para proteinas de celulas nk de union a nkp46.
|
IL305818A
(en)
|
2021-03-29 |
2023-11-01 |
Daiichi Sankyo Co Ltd |
Multispecific stable compound and its use
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
WO2022223651A1
(en)
|
2021-04-23 |
2022-10-27 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of nk cell engaging agent-related adverse effects
|
JP2024517535A
(ja)
|
2021-04-30 |
2024-04-23 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体と抗cd79b抗体薬物コンジュゲートを用いた併用治療の投与
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
KR20240007928A
(ko)
|
2021-05-14 |
2024-01-17 |
제넨테크, 인크. |
Trem2의 효능제
|
CA3219148A1
(en)
|
2021-05-17 |
2022-11-24 |
Frederick G. Vogt |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
AU2022289365A1
(en)
|
2021-06-07 |
2023-12-14 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
BR112023025331A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
IL308531A
(en)
|
2021-06-09 |
2024-01-01 |
Innate Pharma |
Multiple specific antibodies that bind to CD20, NKP46, CD16 and are equipped with IL-2
|
EP4351582A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
JP2023535884A
(ja)
|
2021-06-22 |
2023-08-22 |
ノバルティス アーゲー |
化膿性汗腺炎の処置における使用のための二特異性抗体
|
CN117460532A
(zh)
|
2021-06-23 |
2024-01-26 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
BR112023026985A2
(pt)
|
2021-06-23 |
2024-03-12 |
Toray Industries |
Medicamento para o tratamento e/ou prevenção do câncer, agente que aumenta a eficácia do medicamento em uma composição farmacêutica, agente para aumentar a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
IL308633A
(en)
|
2021-06-25 |
2024-01-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-CTLA-4 antibodies
|
EP4362977A1
(en)
|
2021-06-29 |
2024-05-08 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
EP4363450A1
(en)
|
2021-07-01 |
2024-05-08 |
Compugen Ltd. |
Anti-tigit and anti-pvrig in monotherapy and combination treatments
|
EP4367139A1
(en)
|
2021-07-08 |
2024-05-15 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
KR20240058075A
(ko)
|
2021-07-14 |
2024-05-03 |
스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 |
Cd40을 특이적으로 식별하는 항체 및 이의 응용
|
CN117480180A
(zh)
|
2021-07-14 |
2024-01-30 |
江苏恒瑞医药股份有限公司 |
特异性结合hgfr和egfr的抗原结合分子及其医药用途
|
AU2022311906A1
(en)
|
2021-07-14 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
EP4373270A2
(en)
|
2021-07-22 |
2024-05-29 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CA3227698A1
(en)
|
2021-07-27 |
2023-02-02 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
CN117651566A
(zh)
|
2021-07-27 |
2024-03-05 |
东丽株式会社 |
用于癌的治疗和/或预防的药品
|
JPWO2023008462A1
(sh)
|
2021-07-27 |
2023-02-02 |
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
CN117794954A
(zh)
|
2021-08-03 |
2024-03-29 |
葛兰素史密斯克莱知识产权发展有限公司 |
生物药物组合物和稳定同位素标记肽图谱方法
|
KR20240046524A
(ko)
|
2021-08-07 |
2024-04-09 |
제넨테크, 인크. |
미만성 거대 b-세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
|
IL310698A
(en)
|
2021-08-13 |
2024-04-01 |
Glaxosmithkline Ip Dev Ltd |
Cytotoxic targeting chimeras for CCR2-expressing cells
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
CA3227835A1
(en)
|
2021-08-13 |
2023-02-16 |
Peiling CHEN |
Cytotoxicity targeting chimeras
|
CN117858905A
(zh)
|
2021-08-19 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
多价抗变体fc区抗体及使用方法
|
KR20240049285A
(ko)
|
2021-08-26 |
2024-04-16 |
쿄와 기린 가부시키가이샤 |
Cd116 및 cd131에 결합하는 이중 특이적 항체
|
KR20240049296A
(ko)
|
2021-08-27 |
2024-04-16 |
제넨테크, 인크. |
타우 병증을 치료하는 방법
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
AU2022338463A1
(en)
|
2021-09-03 |
2024-03-21 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
PE20240883A1
(es)
|
2021-09-06 |
2024-04-24 |
Genmab As |
Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
|
TW202328439A
(zh)
|
2021-09-09 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
使用pd-1 talen基因減弱生成til產物之方法
|
AU2022347380A1
(en)
|
2021-09-15 |
2024-04-11 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023041717A1
(en)
|
2021-09-16 |
2023-03-23 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
AU2022345251A1
(en)
|
2021-09-17 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
CN115894689A
(zh)
|
2021-09-30 |
2023-04-04 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023057893A1
(en)
|
2021-10-05 |
2023-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
JPWO2023058723A1
(sh)
|
2021-10-08 |
2023-04-13 |
|
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
WO2023068226A1
(ja)
|
2021-10-18 |
2023-04-27 |
第一三共株式会社 |
抗cd37抗体-薬物コンジュゲート
|
CA3235824A1
(en)
|
2021-10-27 |
2023-05-04 |
Frederick G. Vogt |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
CA3236417A1
(en)
|
2021-11-05 |
2023-05-11 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AU2022389969A1
(en)
|
2021-11-16 |
2024-05-02 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
CA3235206A1
(en)
|
2021-11-16 |
2023-05-25 |
Davide BASCO |
Novel molecules for therapy and diagnosis
|
AU2022392822A1
(en)
|
2021-11-18 |
2024-05-02 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
CA3238627A1
(en)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
TW202334238A
(zh)
|
2021-11-30 |
2023-09-01 |
日商第一三共股份有限公司 |
蛋白酶分解性遮蔽抗體
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
CA3240565A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies and methods of use
|
WO2023126822A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and rasg12c inhibitor
|
AU2022429904A1
(en)
|
2021-12-28 |
2024-06-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and atr inhibitor
|
AR128222A1
(es)
|
2022-01-07 |
2024-04-10 |
Johnson & Johnson Entpr Innovation Inc |
MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
|
WO2023139292A1
(en)
|
2022-01-24 |
2023-07-27 |
Cambridge Enterprise Limited |
Tau therapy
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2023159182A1
(en)
|
2022-02-18 |
2023-08-24 |
Rakuten Medical, Inc. |
Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
|
WO2023161881A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023161877A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for integrin avb6-expressing cells
|
WO2023161878A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for folate receptor-expressing cells
|
WO2023161875A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
|
WO2023161874A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
|
WO2023161879A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
|
WO2023161876A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for cxcr3-expressing cells
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
US20240103010A1
(en)
|
2022-03-18 |
2024-03-28 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
TW202405009A
(zh)
|
2022-03-30 |
2024-02-01 |
瑞士商諾華公司 |
使用抗利尿鈉肽受體1(npr1)抗體治療障礙之方法
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
TW202408562A
(zh)
|
2022-04-13 |
2024-03-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
WO2023209591A1
(en)
|
2022-04-27 |
2023-11-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023212304A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202400650A
(zh)
|
2022-05-11 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體與cd47抑制劑之組合
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237706A2
(en)
|
2022-06-08 |
2023-12-14 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
US20240132622A1
(en)
|
2022-07-22 |
2024-04-25 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024026496A1
(en)
|
2022-07-28 |
2024-02-01 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024031032A1
(en)
|
2022-08-05 |
2024-02-08 |
Bristol-Myers Squibb Company |
Anti-ctla-4 antibodies for treatment of kras mutant cancers
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024044675A1
(en)
|
2022-08-25 |
2024-02-29 |
Beigene, Ltd. |
Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024097741A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100200A1
(en)
|
2022-11-09 |
2024-05-16 |
Cis Pharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
US20240190978A1
(en)
|
2022-11-15 |
2024-06-13 |
CSBioAsset LLC |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
WO2024116094A1
(en)
|
2022-11-30 |
2024-06-06 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugates and dnmt inhibitors
|